Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
138
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
REFERENCES
1. Jhavar S, Sarin R, Mulherkar R, Benner A, Agarwal JP,
Dinshaw K. Glutathione S-transferase M1 or T1 null
genotype as a risk factor for developing multiple primary
neoplasms in the upper aero -digestive tract, in Indian
males using tobacco. Oral Oncol. 2004 Jan;40(1):84 -91.
2. Copper MP, Triesscheijn M, Tan IB, Ruevekamp MC,
Stewart FA. Photodynamic therapy in the treatment of
multiple primary tumours in the head and neck, located
to the oral cavity and oropharynx. Clin Otolaryngol. 2007
Jun;32(3):185-9.
3. WHO. International Statist ical Classif ication of Diseases
and Related Health Problems. . 10th Revision, 2nd ed,
Geneva: WHO. 2003.
4. Macpherson LM, McCann MF, Gibson J, Binnie VI,
Stephen KW. The role of primary healthcare
professionals in oral cancer prevention and detection. Br
Dent J. 2003 Sep 13;195(5):277-81; discussion 63.
5. Thompson L. World Health Organization classif icat ion of
tumours: pathology and genetics of head and neck
tumours. Ear Nose Throat J. 2006 Feb;85(2):74.
6. Gale N, Michaels L, Luzar B, Poljak M, Zidar N,
Fischinger J, et al. Current review on squamous
intraepithelial lesions of the larynx. Histopathology. 2009
May;54(6):639-56.
7. Sarode SC, Sarode GS, Karmarkar S, Tupkari JV. A new
classif icat ion for potential ly malignant disorders of the
oral cavity. Oral Oncol. 2011 Jun 27.
8. Dias GS, Almeida AP. A histological and clinical study on
oral cancer: descriptive analyses of 365 cases. Med Oral
Patol Oral Cir Bucal. 2007 Dec;12(7):E474-8.
139
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
9. Stokes A. Comment on "Oral Oncology editorial --
Continued misrepresentation of KB cel ls as being of oral
cancer phenotype requires act ion" [O'Neill ID. Oral Oncol
2009;45(10):e117-118]. Oral Oncol. 2010 May;46(5):e38.
10. Yanofsky VR, Mercer SE, Phelps RG. Histopathological
variants of cutaneous squamous cell carcinoma: a
review. J Skin Cancer. 2011;2011:210813.
11. Quaedvlieg PJ, Creytens DH, Epping GG, Peutz -Kootstra
CJ, Nieman FH, Thissen MR, et al. Histopathological
characteristics of metastasizing squamous cell
carcinoma of the skin and lips. Histopathology. 2006
Sep;49(3):256-64.
12. Chen RB, Suzuki K, Nomura T, Nakajima T. Flow
cytometric analysis of squamous cell carcinomas of the
oral cavity in relat ion to lymph node metastasis. J Oral
Maxil lofac Surg. 1993 Apr;51(4):397 -401.
13. Al-Rawi NH, Talabani NG. Squamous cell carcinoma of
the oral cavity: a case series analysis of clinical
presentat ion and histological grading of 1,425 cases from
Iraq. Clin Oral Investig. 2008 Mar;12(1):15 -8.
14. Cardesa A, Gale N, Nadal A, Zidar N. Squamous cell
carcinoma. In: Barnes L, Eveson JW, Reichart P,
Sidransky D (Eds): World Health Organization
Classif icat ion of Tumours. Pathology & Genetics. Head
and Neck Tumours. IARC Press: Lyon, 2005. 2005:
119-23.
15. Silveira EJ, Godoy GP, Lins RD, Arruda Mde L, Ramos
CC, Freitas Rde A, et al. Correlation of cl inical,
histological, and cytokerat in prof i les of squamous cell
carcinoma of the oral tongue with prognosis. Int J Surg
Pathol. 2007 Oct;15(4):376-83.
16. Fang KH, Kao HK, Cheng MH, Chang YL, Tsang NM,
Huang YC, et al. Histological dif ferentiation of primary
140
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
oral squamous cell carcinomas in an area of betel quid
chewing prevalence. Otolaryngol Head Neck Surg. 2009
Dec;141(6):743-9.
17. Zhang Z, Helman JI, Li LJ. Lymphangiogenesis,
lymphatic endothelial cells and lymphatic metastasis in
head and neck cancer--a review of mechanisms. Int J
Oral Sci. 2010 Mar;2(1):5 -14.
18. Lim YC, Kim WS, Choi EC. Collision metastasis of
squamous carcinoma of the oral tongue and incidental
thyroid papil lary carcinoma to a single cervical lymph
node. Int J Oral Maxil lofac Surg. 2008 May;37(5):494 -6.
19. Nithya C, Pandey M, Naik B, Ahamed IM. Patterns of
cervical metastasis from carcinoma of the oral tongue.
World J Surg Oncol. 2003 Jul 3;1(1):10.
20. Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z,
Vourvachis M, et al. Clinicopathological parameters,
recurrence, locoregional and distant metastasis in 115
T1-T2 oral squamous cell carcinoma patients. Head Neck
Oncol. 2010;2:9.
21. Woolgar JA, Triantafyl lou A. Pitfalls and procedures in
the histopathological diagnosis of oral and oropharyngeal
squamous cell carcinoma and a review of the role of
pathology in prognosis. Oral Oncol. 2009 Apr -May;45(4-
5):361-85.
22. Swinson B, Jerjes W, El-Maaytah M, Norris P, Hopper C.
Optical techniques in diagnosis of head and neck
malignancy. Oral Oncol. 2006 Mar;42(3):221-8.
23. Upile T, Jerjes W, Betz CS, El Maaytah M, Wright A,
Hopper C. Optical diagnostic techniques in the head and
neck. Dent Update. 2007 Sep;34(7):410-2, 5-6, 9-20
passim.
141
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
24. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer
statistics, 2002. CA Cancer J Clin. 2005 Mar -
Apr;55(2):74-108.
25. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the
world cancer burden: Globocan 2000. Int J Cancer. 2001
Oct 15;94(2):153-6.
26. Franceschi S, Bidoli E, Herrero R, Munoz N. Comparison
of cancers of the oral cavity and pharynx worldwide:
etiological clues. Oral Oncol. 2000 Jan;36(1):106 -15.
27. Mayne ST, Cartmel B, Kirsh V, Goodwin WJ, Jr. Alcohol
and tobacco use prediagnosis and postdiagnosis, and
survival in a cohort of patients with early stage cancers
of the oral cavity, pharynx, and larynx. Cancer Epidemiol
Biomarkers Prev. 2009 Dec;18(12):3368-74.
28. McDowell JD. An overview of epidemiology and common
risk factors for oral squamous cell carcinoma.
Otolaryngol Clin North Am. 2006 Apr;39(2):277 -94.
29. Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G,
Vinoda J, et al. Role of tobacco smoking, chewing and
alcohol drinking in the risk of oral cancer in Trivandrum,
India: a nested case-control design using incident cancer
cases. Oral Oncol. 2008 May;44(5):446-54.
30. Warnakulasuriya S, Scully C. Comprehending the
condition, causes, controversies, control and
consequences. 2. Main risk factors and epidemiology.
Dent Update. 2010 Dec;37(10):710-2.
31. Morger R, Ramseier CA, Rees TD, Burgin WB, Bornstein
MM. Oral mucosal f indings related to tobacco use and
alcohol consumption: a study on Swiss army recruits
involving self -reported and clinical data. Oral Health Prev
Dent. 2010;8(2):143-51.
32. Canova C, Richiardi L, Merlett i F, Pentenero M, Gervasio
C, Tanturri G, et al. Alcohol, tobacco and genetic
142
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
susceptibi l ity in relat ion to cancers of the upper
aerodigestive tract in northern Italy. Tumori. 2010 Jan -
Feb;96(1):1-10.
33. Scutariu MM, Voroneanu M, Ursache M. [Detection
strategies and risk factors in oral cancers]. Rev Med Chir
Soc Med Nat Iasi. 2007 Jan-Mar;111(1):221-7.
34. IARC. International Agency for Research on Cancer
Tobacco smoking IARC Monograph on the evaluation of
carcinogenic r isks of chemicals to humans 1986;38:
1-421.
35. Protano C, Andreoli R, Manini P, Guidotti M, Vital i M. A
tobacco-related carcinogen: assessing the impact of
smoking behaviours of cohabitants on benzene exposure
in chi ldren. Tob Control. 2011 Jul 5.
36. Palmer R, Scully C, Felix DH. Nicotine, smoke and
patches. Br Dent J. 2006 Jan 28;200(2):65.
37. Gil l ison ML. Current topics in the epidemiology of oral
cavity and oropharyngeal cancers. Head Neck. 2007
Aug;29(8):779-92.
38. Warnakulasuriya KA, Ralhan R. Clinical, pathological,
cellular and molecular lesions caused by oral smokeless
tobacco--a review. J Oral Pathol Med. 2007
Feb;36(2):63-77.
39. Ahluwalia K, Ro M, Erwin K, Treadwell H. Racial
disparit ies in oral cancer risk and outcomes. J Cancer
Educ. 2005 Summer;20(2):70-1.
40. Ahluwalia KP. Assessing the oral cancer r isk of South -
Asian immigrants in New York City. Cancer. 2005 Dec
15;104(12 Suppl):2959-61.
41. Weitkunat R, Sanders E, Lee PN. Meta-analysis of the
relat ion between European and American smokeless
tobacco and oral cancer. BMC Public Health. 2007;7:334.
143
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
42. Lambert R, Sauvaget C, de Camargo Cancela M,
Sankaranarayanan R. Epidemiology of cancer f rom the
oral cavity and oropharynx. Eur J Gastroenterol Hepatol.
2011 Aug;23(8):633-41.
43. Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut,
betel quid, oral snuff, cigarette smoking and the risk of
oesophageal squamous-cell carcinoma in South Asians:
A multicentre case-control study. Eur J Cancer. 2011
Jul 4.
44. Priebe SL, Aleksejuniene J, Zed C, Dharamsi S, Thinh
DH, Hong NT, et al. Oral squamous cell carcinoma and
cultural oral r isk habits in Vietnam. Int J Dent Hyg. 2010
Aug;8(3):159-68.
45. Merlett i F, Boffetta P, Ciccone G, Mashberg A, Terracini
B. Role of tobacco and alcoholic beverages in the
etiology of cancer of the oral cavity/oropharynx in Torino,
Italy. Cancer Res. 1989 Sep 1;49(17):4919-24.
46. Pelucchi C, Tramacere I, Boffetta P, Negri E, La Vec chia
C. Alcohol consumption and cancer risk. Nutr Cancer.
2011 Oct;63(7):983-90.
47. Giacosa A, Adam-Blondon AF, Baer-Sinnott S, Barale R,
Bavaresco L, Di Gaspero G, et al. Alcohol and wine in
relat ion to cancer and other diseases. Eur J Cancer
Prev. 2011 Oct 13.
48. Downer M. Where next in oral cancer prevention and
control? Community Dent Health. 2007 Jun;24(2):66 -9.
49. Lachenmeier DW, Monakhova YB. Short -term salivary
acetaldehyde increase due to direct exposure to
alcoholic beverages as an additional cancer risk factor
beyond ethanol metabolism. J Exp Clin Cancer Res.
2011;30:3.
50. Lee SY, Cho NH, Choi EC, Baek SJ, Kim WS, Shin DH,
et al. Relevance of human papil loma virus (HPV)
144
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
infection to carcinogenesis of oral tongue cancer. Int J
Oral Maxil lofac Surg. 2010 Jul;39(7):678-83.
51. Bleyer A. Cancer of the oral cavity and pharynx in young
females: increasing incidence, role of human papilloma
virus, and lack of survival improvement. Semin Oncol.
2009 Oct;36(5):451-9.
52. Hansson BG, Rosenquist K, Antonsson A, Wennerberg J,
Schildt EB, Bladstrom A, et al. Strong associat ion
between infection with human papil lomavirus and oral
and oropharyngeal squamous cell carcinoma: a
population-based case-control study in southern Sweden.
Acta Otolaryngol. 2005 Dec;125(12):1337-44.
53. Campisi G, Giovannell i L. Controversies surrounding
human papilloma virus infection, head & neck vs oral
cancer, implicat ions for prophylaxis and treatment. Head
Neck Oncol. 2009;1:8.
54. Pavia M, Pileggi C, Nobile CG, Angelil lo IF. Association
between fruit and vegetable consumption and oral
cancer: a meta-analysis of observational studies. Am J
Clin Nutr. 2006 May;83(5):1126-34.
55. Day GL, Shore RE, Blot WJ, McLaughlin JK, Austin DF,
Greenberg RS, et al. Dietary factors and second primary
cancers: a follow-up of oral and pharyngeal cancer
patients. Nutr Cancer. 1994;21(3):223 -32.
56. Maserejian NN, Giovannucci E, Rosner B, Zavras A,
Joshipura K. Prospective study of fruits and vegetables
and risk of oral premalignant lesions in men. Am J
Epidemiol. 2006 Sep 15;164(6):556 -66.
57. Nieto A, Sanchez MJ, Quintana MJ, Castellsague X,
Mart inez C, Munoz J, et al. BMI throughout l ife, intake of
vitamin supplements and oral cancer in Spain. IARC Sci
Publ. 2002;156:259-61.
145
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
58. Guha N, Boffetta P, Wunsch Filho V, Eluf Neto J,
Shangina O, Zaridze D, et al. Oral health and risk of
squamous cell carcinoma of the head and neck and
esophagus: results of two multicentric case -control
studies. Am J Epidemiol. 2007 Nov 15;166(10):1159 -73.
59. Lissowska J, Pilarska A, Pilarski P, Samolczyk -Wanyura
D, Piekarczyk J, Bardin-Mikollajczak A, et al. Smoking,
alcohol, diet, dentit ion and sexual pract ices in the
epidemiology of oral cancer in Poland. Eur J Cancer
Prev. 2003 Feb;12(1):25-33.
60. Shah N. Geriatric oral health issues in India. Int Dent J.
2001 Jun;51(3 Suppl) :212-8.
61. Vil la A, Kreimer AR, Pasi M, Polimeni A, Cicciu D,
Strohmenger L, et al. Oral cancer knowledge: a survey
administered to patients in dental departments at large
Italian hospitals. J Cancer Educ. 2011 Sep;26(3):505 -9.
62. Califano J, van der Riet P, Westra W, Nawroz H,
Clayman G, Piantadosi S, et al. Genetic progression
model for head and neck cancer: implicat ions for f ield
cancerizat ion. Cancer Res. 1996 Jun 1;56(11):2488 -92.
63. Yeh KT, Chang JG, Lin TH, Wang YF, Tien N, Chang JY,
et al. Epigenetic changes of tumor suppressor genes,
P15, P16, VHL and P53 in oral cancer. Oncol Rep. 2003
May-Jun;10(3):659-63.
64. Watanabe T, Wang X, Miyakawa A, Shiiba M, Imai Y,
Sato T, et al. Mutat ional state of tumor suppressor genes
(DCC, DPC4) and alterat ion on chromosome 18q21 in
human oral cancer. Int J Oncol. 1997 Dec;11(6):1287 -90.
65. Kim MS, Li SL, Bertolami CN, Cherrick HM, Park NH.
State of p53, Rb and DCC tumor suppressor genes in
human oral cancer cell l ines. Anticancer Res. 1993 Sep -
Oct;13(5A):1405-13.
146
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
66. Scully C. Oncogenes, onco-suppressors, carcinogenesis
and oral cancer. Br Dent J. 1992 Jul 25;173(2):53 -9.
67. Tadokoro K, Ueda M, Ohshima T, Fujita K, Rikimaru K,
Takahashi N, et al. Act ivat ion of oncogenes in human
oral cancer cel ls: a novel codon 13 mutation of c -H-ras-1
and concurrent amplif ications of c -erbB-1 and c-myc.
Oncogene. 1989 Apr;4(4):499-505.
68. Scully C, Bagan JV, Hopper C, Epstein JB. Oral cancer:
current and future diagnostic techniques. Am J Dent.
2008 Aug;21(4):199-209.
69. Liska D, Lyon M, Jones DS. Detoxif ication and
biotransformational imbalances. Explore (NY). 2006
Mar;2(2):122-40.
70. Dekant W. The role of biotransformation and
bioactivation in toxicity. EXS. 2009;99:57 -86.
71. Liska DJ. The detoxif icat ion enzyme systems. Altern Med
Rev. 1998 Jun;3(3):187-98.
72. Xu C, Li CY, Kong AN. Induction of phase I, II and II I
drug metabolism/transport by xenobiotics. Arch Pharm
Res. 2005 Mar;28(3):249-68.
73. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V,
Stangeland LB, et al. A comprehensive analysis of phase
I and phase II metabolism gene polymorphisms and risk
of non-small cell lung cancer in smokers.
Carcinogenesis. 2008 Jun;29(6):1164-9.
74. Landi S, Gemignani F, Moreno V, Gioia -Patricola L,
Chabrier A, Guino E, et al. A comprehensive analysis of
phase I and phase II metabolism gene polymorphisms
and risk of colorectal cancer. Pharmacogenet Genomics.
2005 Aug;15(8):535-46.
75. Zhou S, Kestell P, Baguley BC, Paxton JW. Preclinical
factors inf luencing the relative contributions of Phase I
and II enzymes to the metabolism of the experimental
147
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Biochem Pharmacol. 2003 Jan 1;65(1):109-20.
76. Roos PH, Bolt HM. Cytochrome P450 interact ions in
human cancers: new aspects considering CYP1B1.
Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):187 -202.
77. Kleiner HE, Vulimiri SV, Hatten WB, Reed MJ, Nebert
DW, Jefcoate CR, et al. Role of cytochrome p4501 family
members in the metabolic activation of polycycl ic
aromatic hydrocarbons in mouse epidermis. Chem Res
Toxicol. 2004 Dec;17(12):1667-74.
78. Shimada T, Fujii -Kuriyama Y. Metabolic act ivat ion of
polycycl ic aromatic hydrocarbons to carcinogens by
cytochromes P450 1A1 and 1B1. Cancer Sci. 2004
Jan;95(1):1-6.
79. Hildebrand CE, Gonzalez FJ, McBride OW, Nebert DW.
Assignment of the human 2,3,7,8-tetrachlorodibenzo-p-
dioxin-inducible cytochrome P1-450 gene to chromosome
15. Nucleic Acids Res. 1985 Mar 25;13(6) :2009-16.
80. Jaiswal AK, Gonzalez FJ, Nebert DW. Human P1 -450
gene sequence and correlat ion of mRNA with genetic
dif ferences in benzo[a]pyrene metabolism. Nucleic Acids
Res. 1985 Jun 25;13(12):4503-20.
81. Kawajir i K, Watanabe J, Gotoh O, Tagashira Y, Sogawa
K, Fuji i -Kuriyama Y. Structure and drug inducibil ity of the
human cytochrome P-450c gene. Eur J Biochem. 1986
Sep 1;159(2):219-25.
82. Hosoya T, Harada N, Mimura J, Motohashi H, Takahashi
S, Nakajima O, et al. Inducibi l ity of cytochrome P450 1A1
and chemical carcinogenesis by benzo[a]pyrene in AhR
repressor-deficient mice. Biochem Biophys Res Commun.
2008 Jan 18;365(3):562-7.
83. Dey A, Jones JE, Nebert DW. Tissue- and cell type-
specif ic expression of cytochrome P450 1A1 and
148
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
cytochrome P450 1A2 mRNA in the mouse locali zed in
situ hybridization. Biochem Pharmacol. 1999 Aug
1;58(3):525-37.
84. Singh N, Mitra AK, Garg VK, Agarwal A, Sharma M,
Chaturvedi R, et al. Associat ion of CYP1A1
polymorphisms with breast cancer in North Indian
women. Oncol Res. 2007;16(12):587 -97.
85. Kristiansen W, Haugen TB, Witczak O, Andersen JM,
Fossa SD, Aschim EL. CYP1A1, CYP3A5 and CYP3A7
polymorphisms and testicular cancer susceptibi l ity. Int J
Androl. 2011 Feb;34(1):77-83.
86. Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L,
McLachlan RE, et al. Genetic associat ion study of
CYP1A1 polymorphisms identif ies r isk haplotypes in
nonsmall cell lung cancer. Eur Respir J. 2010
Jan;35(1):152-9.
87. Spurr NK, Gough AC, Stevenson K, Wolf CR. Msp -1
polymorphism detected with a cDNA probe for the P -450
I family on chromosome 15. Nucleic Acids Res. 1987 Jul
24;15(14):5901.
88. Crofts F, Cosma GN, Currie D, Taiol i E, Toniolo P, Garte
SJ. A novel CYP1A1 gene polymorphism in African -
Americans. Carcinogenesis. 1993 Sep;14(9):1729 -31.
89. Crofts F, Taiol i E, Trachman J, Cosma GN, Cu rrie D,
Toniolo P, et al. Functional signif icance of dif ferent
human CYP1A1 genotypes. Carcinogenesis. 1994
Dec;15(12):2961-3.
90. Cascorbi I , Brockmoller J, Roots I. A C4887A
polymorphism in exon 7 of human CYP1A1: populat ion
frequency, mutation linkages, and impact on lung cancer
susceptibi l ity. Cancer Res. 1996 Nov 1;56(21):4965 -9.
91. Hirvonen A, Husgafvel -Pursiainen K, Karjalainen A,
Antti la S, Vainio H. Point -mutational MspI and Ile -Val
149
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
polymorphisms closely l inked in the CYP1A1 gene: lack
of association with susceptibi l i ty to lung cancer in a
Finnish study population. Cancer Epidemiol Biomarkers
Prev. 1992 Sep-Oct;1(6):485-9.
92. Fontana X, Peyrottes I, Rossi C, Leblanc-Talent P, Ettore
F, Namer M, et al. Study of the frequencies of CYP1A1
gene polymorphisms and glutathione S-transferase mu1
gene in primary breast cancers: an update with an
additional 114 cases. Mutat Res. 1998 Jul 17;403(1 -2):
45-53.
93. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ,
McMunn C, et al. Genetic variation in eleven phase I
drug metabolism genes in an ethnically diverse
population. Pharmacogenomics. 2004 Oct;5(7):895 -931.
94. Singhal R, Shankar K, Badger TM, Ronis MJ. Estrogenic
status modulates aryl hydrocarbon receptor --mediated
hepatic gene expression and carcinogenicity.
Carcinogenesis. 2008 Feb;29(2):227-36.
95. Hayashi S, Watanabe J, Nakachi K, Kawajir i K. Genetic
l inkage of lung cancer-associated MspI polymorphisms
with amino acid replacement in the heme binding region
of the human cytochrome P450IA1 gene. J Biochem.
1991 Sep;110(3):407-11.
96. Zhang ZY, Fasco MJ, Huang L, Guengerich FP,
Kaminsky LS. Characterization of purif ied human
recombinant cytochrome P4501A1-I le462 and -Val462:
assessment of a role for the rare allele in
carcinogenesis. Cancer Res. 1996 Sep 1;56(17):3926 -33.
97. Persson I, Johansson I, Ingelman-Sundberg M. In vitro
kinetics of two human CYP1A1 variant enzymes
suggested to be associated with interindividual
dif ferences in cancer susceptibi l ity. Biochem Biophys
Res Commun. 1997 Feb 3;231(1):227-30.
150
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
98. Chevalier D, Allorge D, Lo-Guidice JM, Cauff iez C,
Lhermitte M, Lafitte JJ, et al. Detection of known and two
novel (M331I and R464S) missense mutations in the
human CYP1A1 gene in a French Caucasian populat ion.
Hum Mutat. 2001 Apr;17(4):355.
99. Saito T, Egashira M, Kiyotani K, Fu jieda M, Yamazaki H,
Kiyohara C, et al. Novel nonsynonymous polymorphisms
of the CYP1A1 gene in Japanese. Drug Metab
Pharmacokinet. 2003;18(3):218-21.
100. London SJ, Yuan JM, Coetzee GA, Gao YT, Ross RK, Yu
MC. CYP1A1 I462V genetic polymorphism and lung
cancer risk in a cohort of men in Shanghai, China.
Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):
987-91.
101. Chen S, Xue K, Xu L, Ma G, Wu J. Polymorphisms of the
CYP1A1 and GSTM1 genes in relation to individual
susceptibi l ity to lung carcinoma in Chinese populat ion.
Mutat Res. 2001 Jun;458(1-2):41-7.
102. Kawajir i K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M.
Association of CYP1A1 germ l ine polymorphisms with
mutations of the p53 gene in lung cancer. Cancer Res.
1996 Jan 1;56(1):72-6.
103. Kawajir i K, Nakachi K, Imai K, Watanabe J, Hayashi S.
Germ l ine polymorphisms of p53 and CYP1A1 genes
involved in human lung cancer. Carcinogenesis. 1993
Jun;14(6):1085-9.
104. Song N, Tan W, Xing D, Lin D. CYP 1A1 polymorphism
and risk of lung cancer in relation to tobacco smoking: a
case-control study in China. Carcinogenesis. 2001
Jan;22(1):11-6.
105. Ozturk O, Isbir T, Yaylim I, Kocaturk CI, Gurses A. GST
M1 and CYP1A1 gene polymorphism and daily fruit
151
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
consumption in Turkish patients with non-small cell lung
carcinomas. In Vivo. 2003 Nov-Dec;17(6):625-32.
106. Sreelekha TT, Rajesh M, Anil Kumar V, Madhavan J,
Balaram P. CYP1A1m2 polymorphisms regulate estrogen
and interleukin-6 in lung cancer. Mol Med Report. 2010
Nov-Dec;3(6):971-6.
107. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V,
Brogger A, et al. Human CYP1A1 (cytochrome P(1)450)
gene: lack of associat ion between the Msp I restrict ion
fragment length polymorphism and incidence of lung
cancer in a Norwegian populat ion. Pharmacogenetics.
1991 Oct;1(1):20-5.
108. Yuan X, Zhou G, Zhai Y, Xie W, Cui Y, Cao J, et al. Lack
of association between the functional polymorphisms in
the estrogen-metabolizing genes and risk for
hepatocellular carcinoma. Cancer Epidemiol Biomarkers
Prev. 2008 Dec;17(12):3621-7.
109. Wu MT, Lee JM, Wu DC, Ho CK, Wang YT, Lee YC, et al.
Genetic polymorphisms of cytochrome P4501A1 and
oesophageal squamous-cell carcinoma in Taiwan. Br J
Cancer. 2002 Aug 27;87(5):529-32.
110. Wang AH, Sun CS, Li LS, Huang JY, Chen QS.
Relat ionship of tobacco smoking CYP1A1 GSTM1 gene
polymorphism and esophageal cancer in Xi 'an. World J
Gastroenterol. 2002 Feb;8(1):49-53.
111. Wang AH, Sun CS, Li LS, Huang JY, Chen QS, Xu DZ.
Genetic susceptibil ity and environmental factors of
esophageal cancer in Xi'an. World J Gastroenterol. 2004
Apr 1;10(7):940-4.
112. Abbas A, Delvinquiere K, Lechevrel M, Lebail ly P,
Gauduchon P, Launoy G, et al. GSTM1, GSTT1, GSTP1
and CYP1A1 genetic polymorphisms and susceptibil ity to
esophageal cancer in a French population: dif ferent
152
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
pattern of squamous cell carcinoma and
adenocarcinoma. World J Gastroenterol. 2004 Dec
1;10(23):3389-93.
113. Morita S, Yano M, Shiozaki H, Tsujinaka T, Ebisui C,
Morimoto T, et al. CYP1A1, CYP2E1 and GSTM1
polymorphisms are not associated with susceptibi l ity to
squamous-cell carcinoma of the esophagus. Int J Cancer.
1997 Apr 10;71(2):192-5.
114. Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX.
CYP1A1, GSTs and mEH polymorphisms and
susceptibi l ity to esophageal carcinoma: study of
population from a high- incidence area in north China.
World J Gastroenterol. 2003 Jul ;9(7):1394-7.
115. Jain M, Kumar S, Ghoshal UC, Mittal B. CYP1A1 Msp1
T/C polymorphism in esophageal cancer: no associat ion
and risk modulat ion. Oncol Res. 2007;16(9):437 -43.
116. Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, et
al. Associat ion studies of CYP1A1 and GSTM1
polymorphisms with esophageal cancer risk: evidence -
based meta-analyses. Arch Med Res. 2009
Apr;40(3):169-79.
117. Lazarevic K, Nagorni A, Rancic N, Milut inovic S, Stosic
L, I l i jev I. Dietary factors and gastric cancer risk:
hospital-based case control study. J BUON. 2010 Jan-
Mar;15(1):89-93.
118. Roth MJ, Abnet CC, Johnson LL, Mark SD, Dong ZW,
Taylor PR, et al. Polymorphic variation of Cyp1A1 is
associated with the risk of gastric cardia cancer: a
prospective case-cohort study of cytochrome P-450 1A1
and GST enzymes. Cancer Causes Control. 2004
Dec;15(10):1077-83.
119. Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship
between genetic polymorphisms of drug-metabolizing
153
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2),
drinking habits, histological subtypes, and p53 gene
point mutations in Japanese patients with gastric cancer.
J Gastroenterol. 2004;39(3):220-30.
120. Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H,
Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene
polymorphisms and susceptibil ity to colorectal and
gastric cancer among Lebanese. Genet Test Mol
Biomarkers. 2011 Jun;15(6):423-9.
121. Sivaraman L, Leatham MP, Yee J, Wilkens LR, Lau AF,
Le Marchand L. CYP1A1 genetic polymorphisms and in
situ colorectal cancer. Cancer Res. 1994 Jul
15;54(14):3692-5.
122. Slattery ML, Samowtiz W, Ma K, Murtaugh M, Sweeney
C, Levin TR, et al. CYP1A1, cigarette smoking, and colon
and rectal cancer. Am J Epidemiol. 2004 Nov
1;160(9):842-52.
123. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R,
Sull ivan F, et al. A pharmacogenetic study to investigate
the role of dietary carcinogens in the etiology of
colorectal cancer. Carcinogenesis. 2002
Nov;23(11):1839-49.
124. Kiss I, Sandor J, Pajkos G, Bogner B, Hegedus G, Ember
I. Colorectal cancer risk in relation to genetic
polymorphism of cytochrome P450 1A1, 2E1, and
glutathione-S-transferase M1 enzymes. Anticancer Res.
2000 Jan-Feb;20(1B):519-22.
125. Litt le J, Sharp L, Masson LF, Brockton NT, Cotton SC,
Haites NE, et al. Colorectal cancer and genetic
polymorphisms of CYP1A1, GSTM1 and GSTT1: a case -
control study in the Grampian region of Scotland. Int J
Cancer. 2006 Nov 1;119(9):2155-64.
154
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
126. Pereira Serafim PV, Cotrim Guerreiro da Silva ID,
Manoukias Forones N. Relationship between genetic
polymorphism of CYP1A1 at codon 462 (Ile462Val) in
colorectal cancer. Int J Biol Markers. 2008 Jan-
Mar;23(1):18-23.
127. Jin JQ, Hu YY, Niu YM, Yang GL, Wu YY, Leng WD, et
al. CYP1A1 Ile462Val polymorphism contributes to
colorectal cancer risk: a meta-analysis. World J
Gastroenterol. 2011 Jan 14;17(2):260 -6.
128. Zheng Y, Wang JJ, Sun L, Li HL. Association between
CYP1A1 polymorphism and colorectal cancer risk: a
meta-analysis. Mol Biol Rep. 2011 Jun 28.
129. Yu MW, Chiu YH, Yang SY, Santel la RM, Chern HD, Liaw
YF, et al. Cytochrome P450 1A1 genetic polymorphisms
and risk of hepatocellular carc inoma among chronic
hepatit is B carriers. Br J Cancer. 1999 May;80(3 -4):598-
603.
130. Silvestri L, Sonzogni L, De Silvestri A, Gritt i C, Foti L,
Zavaglia C, et al. CYP enzyme polymorphisms and
susceptibi l ity to HCV-related chronic l iver disease and
liver cancer. Int J Cancer. 2003 Apr 10;104(3):310 -7.
131. Vineis P. The relationship between polymorphisms of
xenobiotic metabolizing enzymes and susceptibil ity to
cancer. Toxicology. 2002 Dec 27;181 -182:457-62.
132. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E,
Heinze G, et al. Estrogen-metabolizing gene
polymorphisms in the assessment of breast carcinoma
risk and f ibroadenoma risk in Caucasian women. Cancer.
2004 Jul 15;101(2):264-9.
133. Miyoshi Y, Takahashi Y, Egawa C, Noguchi S. Breast
cancer r isk associated with CYP1A1 genetic
polymorphisms in Japanese women. Breast J. 2002 Jul -
Aug;8(4):209-15.
155
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
134. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM,
Shen CY. Breast cancer r isk associated with genotype
polymorphism of the estrogen-metabolizing genes
CYP17, CYP1A1, and COMT: a multigenic study on
cancer susceptibil ity. Cancer Res. 1999 Oct
1;59(19):4870-5.
135. Masson LF, Sharp L, Cotton SC, Litt le J. Cytochrome P -
450 1A1 gene polymorphisms and risk of breast cancer:
a HuGE review. Am J Epidemiol. 2005 May
15;161(10):901-15.
136. Basham VM, Pharoah PD, Healey CS, Luben RN, Day
NE, Easton DF, et al. Polymorphisms in CYP1A1 and
smoking: no association with breast cancer r isk.
Carcinogenesis. 2001 Nov;22(11):1797-800.
137. Laden F, Ishibe N, Hankinson SE, Wolff MS, Gert ig DM,
Hunter DJ, et al . Polychlorinated biphenyls, cytochrome
P450 1A1, and breast cancer r isk in the Nurses' Health
Study. Cancer Epidemiol Biomarkers Prev. 2002
Dec;11(12):1560-5.
138. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D,
Willett WC, Speizer FE, et al. Cigarette smoking,
cytochrome P450 1A1 polymorphisms, and breast cancer
risk in the Nurses' Health Study. Cancer Res. 1998 Feb
15;58(4):667-71.
139. Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura
J, Irahara N, et al. Association of genetic polymorphisms
in CYP19 and CYP1A1 with the oestrogen receptor-
positive breast cancer risk. Eur J Cancer. 2003
Nov;39(17):2531-7.
140. Okobia M, Bunker C, Zmuda J, Kammerer C, Vogel V,
Uche E, et al. Cytochrome P4501A1 genetic
polymorphisms and breast cancer risk in Nigerian
156
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
women. Breast Cancer Res Treat. 2005 Dec;94(3):285 -
93.
141. Boyapati SM, Shu XO, Gao YT, Cai Q, Jin F, Zheng W.
Polymorphisms in CYP1A1 and breast carcinoma risk in
a population-based case-control study of Chinese
women. Cancer. 2005 Jun 1;103(11):2228-35.
142. Moysich KB, Shields PG, Freudenheim JL, Schisterman
EF, Vena JE, Kostyniak P, et al. Polychlorinated
biphenyls, cytochrome P4501A1 polymorphism, and
postmenopausal breast cancer risk. Cancer Epidemiol
Biomarkers Prev. 1999 Jan;8(1):41-4.
143. Huang CS, Shen CY, Chang KJ, Hsu SM, Chern HD.
Cytochrome P4501A1 polymorphism as a susceptibi l i ty
factor for breast cancer in postmenopausal Chinese
women in Taiwan. Br J Cancer. 1999 Aug;80(11):1838 -
43.
144. Taioli E, Bradlow HL, Garbers SV, Sepkovic DW,
Osborne MP, Trachman J, et al. Role of estradiol
metabolism and CYP1A1 polymorphisms in breast cancer
risk. Cancer Detect Prev. 1999;23(3):232-7.
145. Chacko P, Joseph T, Mathew BS, Rajan B, Pil lai MR.
Role of xenobiotic metabolizing gene polymorphisms in
breast cancer susceptibil ity and treatment outcome.
Mutat Res. 2005 Mar 7;581(1 -2):153-63.
146. da Fonte de Amorim L, Rossini A, Mendonca G, Lotsch
P, de Almeida Simao T, de Moura Gallo C, et al.
CYP1A1, GSTM1, and GSTT1 polymorphisms and breast
cancer risk in Brazil ian women. Cancer Lett. 2002 Jul
26;181(2):179-86.
147. Li Y, Mil l ikan RC, Bell DA, Cui L, Tse CK, Newman B, et
al. Polychlorinated biphenyls, cytochrome P450 1A1
(CYP1A1) polymorphisms, and breast cancer risk among
African American women and white women in North
157
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
Carolina: a population-based case-control study. Breast
Cancer Res. 2005;7(1):R12-8.
148. Chen C, Huang Y, Li Y, Mao Y, Xie Y. Cytochrome P450
1A1 (CYP1A1) T3801C and A2455G polymorphisms in
breast cancer r isk: a meta-analysis. J Hum Genet.
2007;52(5):423-35.
149. Sergentanis TN, Economopoulos KP. Four
polymorphisms in cytochrome P450 1A1 (CYP1A1) gene
and breast cancer r isk: a meta-analysis. Breast Cancer
Res Treat. 2010 Jul;122(2):459-69.
150. Kraj inovic M, Ghadirian P, Richer C, Sinnett H, Gandini
S, Perret C, et al. Genetic susceptibil ity to breast cancer
in French-Canadians: role of carcinogen-metabolizing
enzymes and gene-environment interact ions. Int J
Cancer. 2001 Apr 15;92(2):220-5.
151. Zhang Y, Wise JP, Holford TR, Xie H, Boyle P, Zahm SH,
et al. Serum polychlorinated biphenyls, cytochrome P -
450 1A1 polymorphisms, and risk of breast cancer in
Connecticut women. Am J Epidemiol. 2004 Dec
15;160(12):1177-83.
152. Sergentanis TN, Economopoulos KP. Erratum to: Four
polymorphisms in cytochrome P450 1A1 (CYP1A1) gene
and breast cancer r isk: a meta-analysis. Breast Cancer
Res Treat. 2010 Jul 30.
153. Suzuki K, Matsui H, Nakazato H, Koike H, Okugi H,
Hasumi M, et al. Association of the genetic polymorphism
in cytochrome P450 (CYP) 1A1 with risk of familial
prostate cancer in a Japanese population: a case -control
study. Cancer Lett. 2003 Jun 10;195(2):177-83.
154. Murata M, Watanabe M, Yamanaka M, Kubota Y, I to H,
Nagao M, et al. Genetic polymorphisms in cytochrome
P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S -
transferase (GST) M1 and GSTT1 and susceptibil ity to
158
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
prostate cancer in the Japanese population. Cancer Lett.
2001 Apr 26;165(2):171-7.
155. Sterl ing KM, Jr., Cutroneo KR. Constitutive and inducible
expression of cytochromes P4501A (CYP1A1 and
CYP1A2) in normal prostate and prostate cancer cel ls. J
Cell Biochem. 2004 Feb 1;91(2):423-9.
156. Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA,
Wiley KE, et al. Polymorphisms in the CYP1A1 gene are
associated with prostate cancer risk. Int J Cancer. 2003
Sep 1;106(3):375-8.
157. Aktas D, Hascicek M, Sozen S, Ozen H, Tuncbilek E.
CYP1A1 and GSTM1 polymorphic genotypes in patients
with prostate cancer in a Turkish population. Cancer
Genet Cytogenet. 2004 Oct 1;154(1):81-5.
158. Li M, Guan TY, Li Y, Na YQ. Polymorphisms of GSTM1
and CYP1A1 genes and their genetic susceptibi l ity to
prostate cancer in Chinese men. Chin Med J (Engl). 2008
Feb 20;121(4):305-8.
159. Sil ig Y, Pinarbasi H, Gunes S, Ayan S, Bagci H,
Cetinkaya O. Polymorphisms of CYP1A1, GSTM1,
GSTT1, and prostate cancer risk in Turkish population.
Cancer Invest. 2006 Feb;24(1):41-5.
160. Lima MM, Jr., Oliveira MN, Granja F, Trindade AC, De
Castro Santos LE, Ward LS. Lack of association of
GSTT1, GSTM1, GSTO1, GSTP1 and CYP1A1
polymorphisms for susceptibi l ity and outcome in Brazil ian
prostate cancer patients. Folia Biol (Praha).
2008;54(3):102-8.
161. Rodrigues IS, Kuasne H, Losi -Guembarovski R, Fuganti
PE, Gregorio EP, Kishima MO, et al. Evaluation of the
inf luence of polymorphic variants CYP1A1*2B,
CYP1B1*2, CYP3A4*1B, GSTM1*0, and GSTT1*0 in
prostate cancer. Urol Oncol. 2010 Sep 28.
159
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
162. Shaik AP, Jamil K, Das P. CYP1A1 polymorphisms and
risk of prostate cancer: a meta-analysis. Urol J. 2009
Spring;6(2):78-86.
163. Sohda T, Shimizu M, Kamimura S, Okumura M.
Immunohistochemical demonstrat ion of ethanol -inducible
P450 2E1 in rat brain. Alcohol Alcohol Suppl.
1993;1B:69-75.
164. Howard LA, Miksys S, Hoffmann E, Mash D, Tyndale RF.
Brain CYP2E1 is induced by nicot ine and ethanol in rat
and is higher in smokers and alcoholics. Br J Pharmacol.
2003 Apr;138(7):1376-86.
165. Yue J, Khokhar J, Miksys S, Tyndale RF. Differential
induction of ethanol-metabolizing CYP2E1 and nicotine -
metabolizing CYP2B1/2 in rat l iver by chronic nicot ine
treatment and voluntary ethanol intake. Eur J Pharmacol.
2009 May 1;609(1-3):88-95.
166. Seitz HK, Stickel F. Molecular mechanisms of alcohol -
mediated carcinogenesis. Nat Rev Cancer. 2007
Aug;7(8):599-612.
167. Guengerich FP, Kim DH, Iwasaki M. Role of human
cytochrome P-450 IIE1 in the oxidation of many low
molecular weight cancer suspects. Chem Res Toxicol.
1991 Mar-Apr;4(2):168-79.
168. Lewis DF, Bird MG, Parke DV. Molecular modell ing of
CYP2E1 enzymes from rat, mouse and man: an
explanation for species dif ferences in butadiene
metabolism and potential carcinogenicity, and
rationalization of CYP2E substrate specif icity.
Toxicology. 1997 Mar 28;118(2 -3):93-113.
169. Hayashi S, Watanabe J, Kawajiri K. Genetic
polymorphisms in the 5' -f lanking region change
transcriptional regulation of the human cytochrome
P450IIE1 gene. J Biochem. 1991 Oct;110(4):559 -65.
160
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
170. Chen JM, Ferec C, Cooper DN. A systematic analysis of
disease-associated variants in the 3' regulatory regions
of human protein-coding genes I: general principles and
overview. Hum Genet. 2006 Aug;120(1):1 -21.
171. Matthias C, Jahnke V, Fryer AA, Strange RC. [Inf luence
of glutathione s-transferase and cytochrome p450
polymorphisms on prognosis of head and neck cancer].
Laryngorhinootologie. 2002 Jun;81(6):406-12.
172. Gattas GJ, de Carvalho MB, Siraque MS, Curioni OA,
Kohler P, Eluf -Neto J, et al. Genetic polymorphisms of
CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with
head and neck cancer. Head Neck. 2006 Sep;28(9):
819-26.
173. Ye X, Peng T, Liu T, Su Z, Xiao K, Shang L, et al.
[Association between aldehyde dehydrogenase -
2/cytochrome P450 2E1 genetic polymorphism and habit
of alcohol drinking and the susceptibi l ity of
hepatocellular carcinoma]. Wei Sheng Yan Jiu. 2010
Jan;39(1):42-5.
174. Hata S, Miki Y, Fujishima F, Sato R, Okaue A, Abe K, et
al. Cytochrome 3A and 2E1 in human liver t issue:
Individual variations among normal Japanese subjects.
Life Sci. 2010 Mar 13;86(11-12):393-401.
175. Wang Y, Yang H, Li L, Wang H, Zhang C, Yin G, et al.
Association between CYP2E1 genetic polymorphisms and
lung cancer risk: a meta-analysis. Eur J Cancer. 2010
Mar;46(4):758-64.
176. Klinchid J, Chewaskulyoung B, Saeteng S,
Lertprasertsuke N, Kasinrerk W, Cressey R. Effect of
combined genetic polymorphisms on lung cancer risk in
northern Thai women. Cancer Genet Cytogenet. 2009
Dec;195(2):143-9.
161
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
177. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump
BF, Sugimura H, et al. Cytochrome P450IIE1 genetic
polymorphisms, racial variat ion, and lung cancer r isk.
Cancer Res. 1992 Dec 1;52(23):6712-5.
178. Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF,
et al. Impact of genetic polymorphisms in cytochrome
P450 2E1 and glutathione S-transferases M1, T1, and P1
on susceptibi l ity to esophageal cancer among high-risk
individuals in China. Cancer Epidemiol Biomarkers Prev.
2000 Jun;9(6):551-6.
179. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de
Waziers I. Human cytochrome P450 2E1 (CYP2E1): from
genotype to phenotype. Pharmacogenetics. 1996
Jun;6(3):203-11.
180. Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, et
al. Associat ions between cytochrome P4502E1 genotype,
mutagen sensitivity, cigarette smoking and susceptibi l ity
to lung cancer. Carcinogenesis. 1997 May;18(5):967 -73.
181. London SJ, Daly AK, Cooper J, Carpenter CL, Navidi
WC, Ding L, et al. Lung cancer risk in relat ion to the
CYP2E1 Rsa I genetic polymorphism among African -
Americans and Caucasians in Los Angeles County.
Pharmacogenetics. 1996 Apr;6(2):151 -8.
182. Hildesheim A, Chen CJ, Caporaso NE, Cheng YJ, Hoover
RN, Hsu MM, et al. Cytochrome P4502E1 genetic
polymorphisms and risk of nasopharyngeal carcinoma:
results from a case-control study conducted in Taiwan.
Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):
607-10.
183. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez
FJ. Human ethanol-inducible P450IIE1: complete gene
sequence, promoter characterization, chromosome
162
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
mapping, and cDNA-directed expression. Biochemistry.
1988 Dec 13;27(25):9006-13.
184. McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taq
I polymorphism in the human P450IIE1 gene on
chromosome 10 (CYP2E). Nucleic Acids Res. 1987 Dec
10;15(23):10071.
185. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined
analysis of inherited polymorphisms in arylamine N -
acetyltransferase 2, glutathione S-transferases M1 and
T1, microsomal epoxide hydrolase, and cytochrome P450
enzymes as modulators of bladder cancer risk. Cancer
Res. 1996 Sep 1;56(17):3915-25.
186. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M.
Structural and functional characterizat ion of the 5' -
f lanking region of the rat and human cytochrome P450
2E1 genes: identif ication of a polymorphic repeat in the
human gene. Biochem Biophys Res Commun. 1999 Sep
24;263(2):286-93.
187. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek
W. A genetic polymorphism in the regulatory sequences
of human CYP2E1: associat ion with increased
chlorzoxazone hydroxylation in the presence of obesity
and ethanol intake. Toxicol Appl Pharmacol. 1998
Sep;152(1):276-81.
188. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML,
Tabone M, et al. Genetic polymorphism of human
CYP2E1: characterization of two variant al leles. Mol
Pharmacol. 1997 Mar;51(3):370-6.
189. Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day
CP, Crespi CL, et al. Detect ion and characterizat ion of
novel polymorphisms in the CYP2E1 gene.
Pharmacogenetics. 1998 Dec;8(6):543 -52.
163
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
190. Watanabe J, Hayashi S, Nakachi K, Imai K, Suda Y,
Sekine T, et al. PstI and RsaI RFLPs in complete linkage
disequilibrium at the CYP2E gene. Nucleic Acids Res.
1990 Dec 11;18(23):7194.
191. Persson I, Johansson I, Bergl ing H, Dahl ML, Seidegard
J, Rylander R, et al. Genetic polymorphism of
cytochrome P4502E1 in a Swedish populat ion.
Relat ionship to incidence of lung cancer. FEBS Lett.
1993 Mar 22;319(3):207-11.
192. Itoga S, Nomura F, Makino Y, Tomonaga T, Shimada H,
Ochiai T, et al. Tandem repeat polymorphism of the
CYP2E1 gene: an association study with esophageal
cancer and lung cancer. Alcohol Clin Exp Res. 2002
Aug;26(8 Suppl):15S-9S.
193. Kato S, Shields PG, Caporaso NE, Sugimura H, Trivers
GE, Tucker MA, et al. Analysis of cytochrome P450 2E1
genetic polymorphisms in relat ion to human lung cancer.
Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):515 -8.
194. Sugimura H, Hamada GS, Suzuki I, Iwase T, Kiyokawa E,
Kino I, et al. CYP1A1 and CYP2E1 polymorph ism and
lung cancer, case-control study in Rio de Janeiro, Brazi l.
Pharmacogenetics. 1995;5 Spec No:S145-8.
195. Hirvonen A, Husgafvel -Pursiainen K, Antti la S,
Karjalainen A, Vainio H. The human CYP2E1 gene and
lung cancer: DraI and RsaI restriction fragment le ngth
polymorphisms in a Finnish study populat ion.
Carcinogenesis. 1993 Jan;14(1):85-8.
196. Hamada GS, Sugimura H, Suzuki I, Nagura K, Kiyokawa
E, Iwase T, et al. The heme-binding region polymorphism
of cytochrome P450IA1 (CypIA1), rather than the RsaI
polymorphism of IIE1 (CypIIE1), is associated with lung
cancer in Rio de Janeiro. Cancer Epidemiol Biomarkers
Prev. 1995 Jan-Feb;4(1):63-7.
164
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
197. Watanabe J, Yang JP, Eguchi H, Hayashi S, Imai K,
Nakachi K, et al. An Rsa I polymorphism in the CYP2E1
gene does not affect lung cancer risk in a Japanese
population. Jpn J Cancer Res. 1995 Mar;86(3):245 -8.
198. Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A.
Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1
and GSTT1 genes and lung cancer susceptibi l ity in a
north indian population. Mol Cell Biochem. 2004
Nov;266(1-2):1-9.
199. Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, et al.
Cytochrome P450 2E1 DraI polymorphisms in lung
cancer in minority populations. Cancer Epidemiol
Biomarkers Prev. 1998 Jan;7(1):13-8.
200. Uematsu F, Kikuchi H, Motomiya M, Abe T, Ishioka C,
Kanamaru R, et al. Human cytochrome P450IIE1 gene:
DraI polymorphism and susceptibil ity to cancer. Tohoku J
Exp Med. 1992 Oct;168(2):113-7.
201. Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R,
Abe T, et al. Restriction fragment length polymorphism of
the human CYP2E1 (cytochrome P450IIE1) gene and
susceptibi l ity to lung cancer: possible relevance to low
smoking exposure. Pharmacogenetics. 1994 Apr;4(2):58 -
63.
202. Eom SY, Zhang YW, Kim SH, Choe KH, Lee KY, Park JD,
et al. Inf luence of NQO1, ALDH2, and CYP2E1 genetic
polymorphisms, smoking, and alcohol drinking on the risk
of lung cancer in Koreans. Cancer Causes Control. 2009
Mar;20(2):137-45.
203. Zhan P, Wang J, Zhang Y, Qiu LX, Zhao SF, Qian Q, et
al. CYP2E1 Rsa I/Pst I polymorphism is associated with
lung cancer risk among Asians. Lung Cancer. 2010
Jul;69(1):19-25.
165
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
204. Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, et
al. Relat ionship between genetic polymorphisms of
metabolizing enzymes CYP2E1, GSTM1 and Kazakh's
esophageal squamous cell cancer in Xinj iang, China.
World J Gastroenterol. 2005 Jun 28;11(24):3651 -4.
205. Lin D, Tang Y, Peng Q. [Genetic polymorphisms of
cytochrome P450 2E1 and glutathione S-transferase P1
and susceptibi l ity to esophageal cancer]. Zhonghua
Zhong Liu Za Zhi. 1998 Mar;20(2):94-7.
206. Li D, Dandara C, Parker MI. Association of cytochrome
P450 2E1 genetic polymorphisms with squamous cell
carcinoma of the oesophagus. Clin Chem Lab Med.
2005;43(4):370-5.
207. Rossini A, Rapozo DC, Soares Lima SC, Guimaraes DP,
Ferreira MA, Teixeira R, et al. Polymorphisms of GSTP1
and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1,
modify the risk for esophageal cancer in a western
population. Carcinogenesis. 2007 Dec;28(12):2537 -42.
208. Niu Y, Yuan H, Leng W, Pang Y, Gu N, Chen N. CYP2E1
Rsa I/Pst I polymorphism and esophageal cancer risk: a
meta-analysis based on 1,088 cases and 2,238 controls.
Med Oncol. 2011 Mar;28(1):182-7.
209. Kato S, Onda M, Matsukura N, Tokunaga A, Tajir i T, Kim
DY, et al. Cytochrome P4502E1 (CYP2E1) genetic
polymorphism in a case-control study of gastric cancer
and liver disease. Pharmacogenetics. 1995;5 Spec
No:S141-4.
210. Park GT, Lee OY, Kwon SJ, Lee CG, Yoon BC, Hahm JS,
et al. Analysis of CYP2E1 polymorphism for the
determination of genetic susceptibi l ity to gastric cancer
in Koreans. J Gastroenterol Hepatol. 2003 Nov;
18(11):1257-63.
166
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
211. Cai L, Zheng ZL, Zhang ZF. Cytochrome p450 2E1
polymorphisms and the risk of gastric cardia cancer.
World J Gastroenterol. 2005 Mar 28;11(12):1867 -71.
212. Wu MS, Chen CJ, Lin MT, Wang HP, Shun CT, Sheu JC,
et al. Genetic polymorphisms of cytochrome p450 2E1,
glutathione S-transferase M1 and T1, and susceptibi l ity
to gastric carcinoma in Taiwan. Int J Colorectal Dis. 2002
Sep;17(5):338-43.
213. Colombo J, Rossit AR, Caetano A, Borim AA, Wornrath
D, Silva AE. GSTT1, GSTM1 and CYP2E1 genetic
polymorphisms in gastric cancer and chronic gastrit is in
a Brazil ian populat ion. World J Gastroenterol. 2004 May
1;10(9):1240-5.
214. Agudo A, Sala N, Pera G, Capella G, Berenguer A,
Garcia N, et al. No association between polymorphisms
in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric
adenocarcinoma in the European prospective
investigation into cancer and nutrit ion. Cancer Epidemiol
Biomarkers Prev. 2006 May;15(5):1043-5.
215. Masuda G, Tokunaga A, Shirakawa T, Togashi A, Kiyama
T, Kato S, et al. Helicobacter pylori infection, but not
genetic polymorphism of CYP2E1, is highly prevalent in
gastric cancer patients younger than 40 years. Gastric
Cancer. 2007;10(2):98-103.
216. van der Logt EM, Bergevoet SM, Roelofs HM, Te
Morsche RH, Dijk Y, Wobbes T, et al. Role of epoxide
hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome
P450 2E1 or alcohol dehydrogenase genotypes in
susceptibi l ity to colorectal cancer. Mutat Res. 2006 Jan
29;593(1-2):39-49.
217. Gao CM, Takezaki T, Wu JZ, Chen MB, Liu YT, Ding JH,
et al. CYP2E1 Rsa I polymorphism impacts on risk of
colorectal cancer association with smoking and alcohol
167
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
drinking. World J Gastroenterol. 2007 Nov
21;13(43):5725-30.
218. Morita M, Le Marchand L, Kono S, Yin G, Toyomura K,
Nagano J, et al. Genetic polymorphisms of CYP2E1 and
risk of colorectal cancer: the Fukuoka Colorectal Cancer
Study. Cancer Epidemiol Biomarkers Prev. 2009
Jan;18(1):235-41.
219. Yang H, Zhou Y, Zhou Z, Liu J, Yuan X, Matsuo K, et al.
A novel polymorphism rs1329149 of CYP2E1 and a
known polymorphism rs671 of ALDH2 of alcohol
metabolizing enzymes are associated with colorectal
cancer in a southwestern Chinese population. Cancer
Epidemiol Biomarkers Prev. 2009 Sep;18(9):2522 -7.
220. Zhou GW, Hu J, Li Q. CYP2E1 PstI/RsaI polymorphism
and colorectal cancer risk: a meta-analysis. World J
Gastroenterol. 2010 Jun 21;16(23):2949-53.
221. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella
RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and
glutathione S-transferase M1 polymorphisms and
susceptibi l ity to hepatocellular carcinoma.
Gastroenterology. 1995 Oct;109(4):1266-73.
222. Lee HS, Yoon JH, Kamimura S, Iwata K, Watanabe H,
Kim CY. Lack of association of cytochrome P450 2E1
genetic polymorphisms with the risk of human
hepatocellular carcinoma. Int J Cancer. 1997 May
29;71(5):737-40.
223. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata
N, Itoh H, et al. Genetic polymorphisms of tobacco - and
alcohol-related metabolizing enzymes and the risk of
hepatocellular carcinoma. J Cancer Res Clin Oncol. 2003
Jun;129(6):355-60.
224. Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards
RJ, Boobis AR, et al. Immunohistochemical
168
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
demonstration of the expression of CYP2E1 in human
breast tumour and non-tumour tissues. Cancer Lett. 2003
Jul 10;196(2):153-9.
225. Choi JY, Abel J, Neuhaus T, Ko Y, Harth V, Hamajima N,
et al. Role of alcohol and genetic polymorphisms of
CYP2E1 and ALDH2 in breast cancer development.
Pharmacogenetics. 2003 Feb;13(2):67 -72.
226. Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ahmed
SB, Chouchane L. Implicat ion of Xenobiotic Metabo lizing
Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and
NAT2) polymorphisms in breast carcinoma. BMC Cancer.
2008;8:109.
227. Ferreira PM, Medeiros R, Vasconcelos A, Costa S, Pinto
D, Morais A, et al. Associat ion between CYP2E1
polymorphisms and susceptibil ity to prostate cancer. Eur
J Cancer Prev. 2003 Jun;12(3):205-11.
228. Yang J, Wu HF, Zhang W, Gu M, Hua LX, Sui YG, et al.
Polymorphisms of metabolic enzyme genes, l iving habits
and prostate cancer susceptibil ity. Front Biosci.
2006;11:2052-60.
229. Yang J, Qian LX, Wu HF, Xu ZQ, Sui YG, Wang XR, et
al. Genetic polymorphisms in the cytochrome P450 1A1
and 2E1 genes, smoking, drinking and prostate cancer
susceptibi l ity: a case-control study in a Han nationality
population in Southern China. Int J Urol. 2006
Jun;13(6):773-80.
230. Yang J, Gu M, Song NH, Feng NH, Hua LX, Ju XB, et al.
[Correlat ion of prostate cancer susceptibi l ity with genetic
polymorphism of cytochrome P450 2E1, smoking and
drinking: a case-control study in the population of
Nanjing area]. Zhonghua Nan Ke Xue. 2009 Jan;15(1):
7-11.
169
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
231. Decker M, Arand M, Cronin A. Mammalian epoxide
hydrolases in xenobiotic metabolism and signall ing. Arch
Toxicol. 2009 Apr;83(4):297-318.
232. Coller JK, Fritz P, Zanger UM, Siegle I, Eichelbaum M,
Kroemer HK, et al. Distribut ion of microsomal epoxide
hydrolase in humans: an immunohistochemical study in
normal t issues, and benign and malignant tumours.
Histochem J. 2001 Jun;33(6):329-36.
233. Beetham JK, Grant D, Arand M, Garbarino J, Kiyosue T,
Pinot F, et al. Gene evolution of epoxide hydrolases and
recommended nomenclature. DNA Cell Biol. 1995
Jan;14(1):61-71.
234. Taura Ki K, Yamada H, Naito E, Ariyoshi N, Mori Ma MA,
Oguri K. Activation of microsomal epoxide hydrolase by
interaction with cytochromes P450: kinetic analysis of
the association and substrate-specif ic act ivat ion of
epoxide hydrolase function. Arch Biochem Biophys. 2002
Jun 15;402(2):275-80.
235. Taura KI, Yamada H, Hagino Y, Ishii Y, Mori MA, Oguri
K. Interaction between cytochrome P450 and other drug -
metabolizing enzymes: evidence for an associat ion of
CYP1A1 with microsomal epoxide hydrolase and UDP -
glucuronosyltransferase. Biochem Biophys Res Commun.
2000 Jul 14;273(3):1048-52.
236. Shou M, Gonzalez FJ, Gelboin HV. Stereoselective
epoxidation and hydration at the K-region of polycycl ic
aromatic hydrocarbons by cDNA-expressed cytochromes
P450 1A1, 1A2, and epoxide hydrolase. Biochemistry.
1996 Dec 10;35(49):15807-13.
237. Hartsf ield JK, Jr., Sutclif fe MJ, Everett ET, Hassett C,
Omiecinski CJ, Saari JA. Assignment1 of microsomal
epoxide hydrolase (EPHX1) to human chromosome
170
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
1q42.1 by in situ hybridizat ion. Cytogenet Cell Genet.
1998;83(1-2):44-5.
238. Hassett C, Robinson KB, Beck NB, Omiecinski CJ. The
human microsomal epoxide hydrolase gene (EPHX1):
complete nucleotide sequence and structural
characterization. Genomics. 1994 Sep 15;23(2):433 -42.
239. Skoda RC, Demierre A, McBride OW, Gonzalez FJ,
Meyer UA. Human microsomal xenobiotic epoxide
hydrolase. Complementary DNA sequence,
complementary DNA-directed expression in COS-1 cells,
and chromosomal localizat ion. J Biol Chem. 1988 Jan
25;263(3):1549-54.
240. Gaedigk A, Leeder JS, Grant DM. Tissue -specif ic
expression and alternative splicing of human microsomal
epoxide hydrolase. DNA Cell Biol. 1997
Nov;16(11):1257-66.
241. !!! INVALID CITATION !!!
242. Omiecinski CJ, Aicher L, Holubkov R, Checkoway H.
Human peripheral lymphocytes as indicators of
microsomal epoxide hydrolase act ivity in l iver and lung.
Pharmacogenetics. 1993 Jun;3(3):150 -8.
243. Zhu QS, Qian B, Levy D. Regulation of human
microsomal epoxide hydrolase gene (EPHX1) expression
by the transcription factor GATA-4. Biochim Biophys
Acta. 2004 Feb 20;1676(3):251-60.
244. Zhu QS, Qian B, Levy D. CCAAT/enhancer -binding
protein alpha (C/EBPalpha) act ivates transcription of the
human microsomal epoxide hydrolase gene (EPHX1)
through the interaction with DNA-bound NF-Y. J Biol
Chem. 2004 Jul 16;279(29):29902-10.
245. Nebert DW, Gonzalez FJ. P450 genes: structure,
evolution, and regulat ion. Annu Rev Biochem.
1987;56:945-93.
171
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
246. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human
microsomal epoxide hydrolase: genetic polymorphism
and functional expression in vitro of amino acid variants.
Hum Mol Genet. 1994 Mar;3(3):421-8.
247. Baxter SW, Choong DY, Campbell IG. Microsomal
epoxide hydrolase polymorphism and susceptibi l ity to
ovarian cancer. Cancer Lett. 2002 Mar 8;177(1):75 -81.
248. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A,
Yamakido M. Microsomal epoxide hydrolase genotypes
and chronic obstructive pulmonary disease in Japanese.
Int J Mol Med. 2000 Jan;5(1):49-53.
249. Benhamou S, Reinikainen M, Bouchardy C, Dayer P,
Hirvonen A. Association between lung cancer and
microsomal epoxide hydrolase genotypes. Cancer Res.
1998 Dec 1;58(23):5291-3.
250. Smith CA, Harrison DJ. Association between
polymorphism in gene for microsomal epoxide hydrolase
and susceptibi l ity to emphysema. Lancet. 1997 Aug
30;350(9078):630-3.
251. Zhou W, Liu G, Thurston SW, Xu LL, Miller DP, Wain JC,
et al. Genetic polymorphisms in N-acetyltransferase-2
and microsomal epoxide hydrolase, cumulative cigarette
smoking, and lung cancer. Cancer Epidemiol Biomarkers
Prev. 2002 Jan;11(1):15-21.
252. Cajas-Salazar N, Au WW, Zwischenberger JB, Sierra -
Torres CH, Salama SA, Alpard SK, et al. Effect of
epoxide hydrolase polymorphisms on chromosome
aberrat ions and risk for lung cancer. Cancer Genet
Cytogenet. 2003 Sep;145(2):97-102.
253. Gsur A, Zidek T, Schnattinger K, Feik E, Haidinger G,
Hollaus P, et al. Associat ion of microsomal epoxide
hydrolase polymorphisms and lung cancer risk. Br J
Cancer. 2003 Aug 18;89(4):702-6.
172
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
254. Graziano C, Comin CE, Crisci C, Novell i L, Polit i L,
Messerini L, et al. Functional polymorphisms of the
microsomal epoxide hydrolase gene: a reappraisal on a
early-onset lung cancer patients series. Lung Cancer.
2009 Feb;63(2):187-93.
255. Park JY, Schantz SP, Lazarus P. Epoxide hydrolase
genotype and orolaryngeal cancer risk: interact ion with
GSTM1 genotype. Oral Oncol. 2003 Jul;39(5):483 -90.
256. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer
P, Benhamou S, Hirvonen A. High -activity microsomal
epoxide hydrolase genotypes and the risk of oral,
pharynx, and larynx cancers. Cancer Res. 2000 Feb
1;60(3):534-6.
257. Jain M, Ti lak AR, Upadhyay R, Kumar A, Mittal B.
Microsomal epoxide hydrolase (EPHX1), slow (exon 3,
113His) and fast (exon 4, 139Arg) alleles confer
susceptibi l ity to squamous cell esophageal cancer.
Toxicol Appl Pharmacol. 2008 Jul 15;230(2):247 -51.
258. Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone
LG. Role of the CYP2D6, EPHX1, MPO, and NQO1 genes
in the susceptibi l ity to acute lymphoblastic leukemia in
Brazil ian children. Environ Mol Mutagen. 2010
Jan;51(1):48-56.
259. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S,
Rannug A, et al. Microsomal epoxide hydrolase
polymorphisms and lung cancer r isk: a quantitat ive
review. Biomarkers. 2002 May-Jun;7(3):230-41.
260. Erkisi Z, Yaylim-Eraltan I, Turna A, Gormus U, Camlica
H, Isbir T. Polymorphisms in the microsomal epoxide
hydrolase gene: role in lung cancer susceptibil ity and
prognosis. Tumori. 2010 Sep-Oct;96(5):756-63.
261. Sun XW, Ma YY, Wang B. [The interact ion between
microsomal epoxide hydrolase polymorphisms and indoor
173
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
pollut ion in non small cel l lung cancer]. Zhonghua Yu
Fang Yi Xue Za Zhi. 2007 Jun;41 Suppl:30 -4.
262. Habalova V, Salagovic J, Kalina I, Stubna J. Combined
analysis of polymorphisms in glutathione S-transferase
M1 and microsomal epoxide hydrolase in lung cancer
patients. Neoplasma. 2004;51(5):352 -7.
263. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y.
EPHX1 polymorphisms and the risk of lung cancer: a
HuGE review. Epidemiology. 2006 Jan;17(1):89 -99.
264. Li X, Hu Z, Qu X, Zhu J, Li L, Ring BZ, et al. Putat ive
EPHX1 enzyme activity is related with risk of lung and
upper aerodigestive tract cancers: a comprehensive
meta-analysis. PLoS One. 2011;6(3):e14749.
265. Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell
DC, Guernsey JR, et al. Associations between genetic
polymorphisms of Phase I and II metabolizing enzymes,
p53 and susceptibil ity to esophageal adenocarcinoma.
Cancer Detect Prev. 2003;27(2):139 -46.
266. Zhang JH, Jin X, Li Y, Wang R, Guo W, Wang N, et al.
Epoxide hydrolase Tyr113His polymorphism is not
associated with susceptibil ity to esophageal squamous
cell carcinoma in population of North China. World J
Gastroenterol. 2003 Dec;9(12):2654-7.
267. Lin YC, Wu DC, Lee JM, Hsu HK, Kao EL, Yang CH, et
al. The associat ion between microsomal epoxide
hydrolase genotypes and esophageal squamous-cell-
carcinoma in Taiwan: interact ion between areca chewing
and smoking. Cancer Lett. 2006 Jun 18;237(2):281 -8.
268. Liu CY, Wu MC, Chen F, Ter -Minassian M, Asomaning K,
Zhai R, et al. A Large-scale genetic association study of
esophageal adenocarcinoma risk. Carcinogenesis. 2010
Jul;31(7):1259-63.
174
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
269. Ihsan R, Chattopadhyay I, Phukan R, Mishra AK,
Purkayastha J, Sharma J, et al. Role of epoxide
hydrolase 1 gene polymorphisms in esophageal cancer in
a high-risk area in India. J Gastroenterol Hepatol. 2010
Aug;25(8):1456-62.
270. Agudo A, Sala N, Pera G, Capella G, Berenguer A,
Garcia N, et al. Polymorphisms in metabolic genes
related to tobacco smoke and the risk of gastric cancer
in the European prospective investigation into cancer
and nutrit ion. Cancer Epidemiol Biomarkers Prev. 2006
Dec;15(12):2427-34.
271. Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna
F, Rausei S, Arzani D, et al. Polymorphisms in metabolic
genes, their combination and interaction with tobacco
smoke and alcohol consumption and risk of gastric
cancer: a case-control study in an Italian population.
BMC Cancer. 2007;7:206.
272. Ikeda S, Sasazuki S, Natsukawa S, Shaura K, Koizumi Y,
Kasuga Y, et al. Screening of 214 single nucleotide
polymorphisms in 44 candidate cancer susceptibi l ity
genes: a case-control study on gastric and colorectal
cancers in the Japanese population. Am J Gastroenterol.
2008 Jun;103(6):1476-87.
273. Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson
SE, Hunter DJ. Epoxide hydrolase polymorphisms,
cigarette smoking and risk of colorectal adenoma in the
Nurses' Health Study and the Health Professionals
Follow-up Study. Carcinogenesis. 2004 Jul;25(7):1211 -8.
274. Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M,
Schoen RE, et al. Microsomal epoxide hydrolase
polymorphisms and risk for advanced colorectal
adenoma. Cancer Epidemiol Biomarkers Prev. 2005
Jan;14(1):152-7.
175
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
275. Mitrou PN, Watson MA, Loktionov AS, Cardwell C,
Gunter MJ, Atkin WS, et al. Role of NQO1C609T and
EPHX1 gene polymorphisms in the association of
smoking and alcohol with sporadic distal colorectal
adenomas: results from the UKFSS Study.
Carcinogenesis. 2007 Apr;28(4):875 -82.
276. Kiss I, Orsos Z, Gombos K, Bogner B, Csejtei A, Tibold
A, et al. Association between al lel ic polymorphisms of
metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1,
mEH) and occurrence of colorectal cancer in Hungary.
Anticancer Res. 2007 Jul -Aug;27(4C):2931-7.
277. Skjelbred CF, Saebo M, Hjartaker A, Grotmol T,
Hansteen IL, Tveit KM, et al. Meat, vegetables and
genetic polymorphisms and the risk of colorectal
carcinomas and adenomas. BMC Cancer. 2007;7:228.
278. Raimondi S, Botteri E, Iodice S, Lowenfels AB,
Maisonneuve P. Gene-smoking interaction on colorectal
adenoma and cancer r isk: review and meta -analysis.
Mutat Res. 2009 Nov 2;670(1-2):6-14.
279. Pande M, Amos CI, Eng C, Frazier ML. Interact ions
between cigarette smoking and selected polymorphisms
in xenobiot ic metabolizing enzymes in risk for colorectal
cancer: A case-only analysis. Mol Carcinog. 2010
Nov;49(11):974-80.
280. Burnett-Hartman AN, Newcomb PA, Mandelson MT,
Adams SV, Wernli KJ, Shadman M, et al. Colorectal
polyp type and the associat ion with charred meat
consumption, smoking, and microsomal epoxide
hydrolase polymorphisms. Nutr Cancer. 2011
May;63(4):583-92.
281. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper
ML, Zhou T, et al. Susceptibil ity to hepatocellular
carcinoma is associated with genetic variat ion in the
176
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
enzymatic detoxif ication of af latoxin B1. Proc Natl Acad
Sci U S A. 1995 Mar 14;92(6):2384-7.
282. Tiemersma EW, Omer RE, Bunschoten A, van't Veer P,
Kok FJ, Idris MO, et al. Role of genetic polymorphism of
glutathione-S-transferase T1 and microsomal epoxide
hydrolase in af latoxin-associated hepatocellular
carcinoma. Cancer Epidemiol Biomarkers Prev. 2001
Jul;10(7):785-91.
283. Kelly EJ, Erickson KE, Sengstag C, Eaton DL.
Expression of human microsomal epoxide hydrolase in
Saccharomyces cerevisiae reveals a functional role in
af latoxin B1 detoxif icat ion. Toxicol Sci. 2002
Jan;65(1):35-42.
284. Sonzogni L, Si lvestri L, De Silvestri A, Gritt i C, Foti L,
Zavaglia C, et al. Polymorphisms of microsomal epoxide
hydrolase gene and severity of HCV-related l iver
disease. Hepatology. 2002 Jul;36(1):195-201.
285. Kiran M, Chawla YK, Kaur J. Glutathione-S-transferase
and microsomal epoxide hydrolase polymorphism and
viral-related hepatocellular carcinoma risk in India. DNA
Cell Biol. 2008 Dec;27(12):687-94.
286. Kiran M, Chawla YK, Jain M, Kaur J. Haplotypes of
microsomal epoxide hydrolase and x-ray cross-
complementing group 1 genes in Indian hepatocellular
carcinoma patients. DNA Cell Biol. 2009 Nov;28(11):
573-7.
287. Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R,
Adamek J, et al. Breast cancer: role of polymorphisms in
biotransformation enzymes. Eur J Hum Genet. 2004
Oct;12(10):848-54.
288. Spurdle AB, Chang JH, Byrnes GB, Chen X, Dite GS,
McCredie MR, et al. A systematic approach to analysing
gene-gene interactions: polymorphisms at the
177
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
microsomal epoxide hydrolase EPHX and glutathione S -
transferase GSTM1, GSTT1, and GSTP1 loci and breast
cancer risk. Cancer Epidemiol Biomarkers Prev. 2007
Apr;16(4):769-74.
289. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl
CB, Rabstein S, et al. Breast cancer: a candidate gene
approach across the estrogen metabolic pathway. Breast
Cancer Res Treat. 2008 Mar;108(1):137-49.
290. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird
NM, Khuhaprema T, et al. Genetic polymorphisms of
estrogen metabolizing enzyme and breast cancer risk in
Thai women. Int J Cancer. 2009 Aug 15;125(4):837 -43.
291. Figer A, Friedman T, Manguoglu AE, Flex D, Vaz ina A,
Novikov I, et al. Analysis of polymorphic patterns in
candidate genes in Israeli patients with prostate cancer.
Isr Med Assoc J. 2003 Oct;5(10):741-5.
292. Nock NL, Liu X, Cicek MS, Li L, Macarie F, Rybicki BA,
et al. Polymorphisms in polycycl ic aromatic hydrocarbon
metabolism and conjugation genes, interactions with
smoking and prostate cancer risk. Cancer Epidemiol
Biomarkers Prev. 2006 Apr;15(4):756-61.
293. Nock NL, Tang D, Rundle A, Neslund-Dudas C, Savera
AT, Bock CH, et al. Associat ions between smoking,
polymorphisms in polycycl ic aromatic hydrocarbon (PAH)
metabolism and conjugation genes and PAH-DNA
adducts in prostate tumors dif fer by race. Cancer
Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236 -45.
294. Figueroa JD, Malats N, Garcia -Closas M, Real FX,
Silverman D, Kogevinas M, et al. Bladder cancer r isk and
genetic variat ion in AKR1C3 and other metabolizing
genes. Carcinogenesis. 2008 Oct;29(10):1955-62.
295. Riddle B, Jencks WP. Acetyl -coenzyme A: arylamine N-
acetyltransferase. Role of the acetyl -enzyme
178
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
intermediate and the effects of substituents on the rate. J
Biol Chem. 1971 May 25;246(10):3250-8.
296. Butcher NJ, Boukouvala S, Sim E, Minchin RF.
Pharmacogenetics of the arylamine N-acetyltransferases.
Pharmacogenomics J. 2002;2(1):30-42.
297. Grant DM, Goodfellow GH, Sugamori K, Durette K.
Pharmacogenetics of the human arylamine N-
acetyltransferases. Pharmacology. 2000 Sep;61(3):
204-11.
298. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping
human polymorphic arylamine N-acetyltransferase:
identif icat ion of new slow allotypic variants.
Pharmacogenetics. 1992 Oct;2(5):217 -26.
299. Dorne JL, Walton K, Renwick AG. Polymorphic CYP2C19
and N-acetylat ion: human variabil ity in kinetics and
pathway-related uncertainty factors. Food Chem Toxicol.
2003 Feb;41(2):225-45.
300. Evans DA. N-acetyltransferase. Pharmacol Ther.
1989;42(2):157-234.
301. Meyer UA, Zanger UM. Molecular mechanisms of genetic
polymorphisms of drug metabolism. Annu Rev Pharmacol
Toxicol. 1997;37:269-96.
302. Delomenie C, Sica L, Grant DM, Krishnamoorthy R,
Dupret JM. Genotyping of the polymorphic N-
acetyltransferase (NAT2*) gene locus in two native
African populat ions. Pharmacogenetics. 1996
Apr;6(2):177-85.
303. Fret land AJ, Leff MA, Doll MA, Hein DW. Functional
characterization of human N-acetyltransferase 2 (NAT2)
single nucleotide polymorphisms. Pharmacogenetics.
2001 Apr;11(3):207-15.
304. Hein DW, Fretland AJ, Doll MA. Effects of single
nucleotide polymorphisms in human N-acetyltransferase
179
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
2 on metabolic act ivat ion (O-acetylation) of heterocyclic
amine carcinogens. Int J Cancer. 2006 Sep
1;119(5):1208-11.
305. Zang Y, Doll MA, Zhao S, States JC, Hein DW.
Functional characterizat ion of single -nucleotide
polymorphisms and haplotypes of human N-
acetyltransferase 2. Carcinogenesis. 2007
Aug;28(8):1665-71.
306. Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez
J. Identif icat ion and prevalence study of 17 allelic
variants of the human NAT2 gene in a white populat ion.
Pharmacogenetics. 1996 Oct;6(5):423 -8.
307. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A,
Sperl ing K, Roots I. Arylamine N-acetyltransferase
(NAT2) mutations and their al lel ic l inkage in unrelated
Caucasian individuals: correlat ion with phenotypic
activity. Am J Hum Genet. 1995 Sep;57(3):581 -92.
308. Dandara C, Masimirembwa CM, Magimba A, Kaaya S,
Sayi J, Sommers DK, et al. Arylamine N-
acetyltransferase (NAT2) genotypes in Africans: the
identif icat ion of a new allele with nucleotide changes
481C>T and 590G>A. Pharmacogenetics. 2003
Jan;13(1):55-8.
309. Burgess EJ, Trafford JA. Acetylator phenotype in
patients with lung carcinoma--a negative report. Eur J
Respir Dis. 1985 Jul;67(1):17-9.
310. Roots I, Drakoulis N, Ploch M, Heinemeyer G,
Loddenkemper R, Minks T, et al. Debrisoquine
hydroxylat ion phenotype, acetylation phenotype, and
ABO blood groups as genetic host factors of lung cancer
risk. Klin Wochenschr. 1988;66 Suppl 11:87-97.
180
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
311. Phil ip PA, Fitzgerald DL, Cartwright RA, Peake MD,
Rogers HJ. Polymorphic N-acetylat ion capacity in lung
cancer. Carcinogenesis. 1988 Mar;9(3):491-3.
312. Sorensen M, Autrup H, Tjonneland A, Overvad K,
Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1,
GSTA1, NQO1 and NAT2 and the risk of lung cancer.
Cancer Lett. 2005 Apr 28;221(2):185-90.
313. Bouchardy C, Mitrunen K, Wikman H, Husgafvel -
Pursiainen K, Dayer P, Benhamou S, et al. N -
acetyltransferase NAT1 and NAT2 genotypes and lung
cancer risk. Pharmacogenetics. 1998 Aug;8(4):291 -8.
314. Mart inez C, Agundez JA, Olivera M, Mart in R, Ladero JM,
Benitez J. Lung cancer and mutations at the polymorphic
NAT2 gene locus. Pharmacogenetics. 1995 Aug;5(4):
207-14.
315. Belogubova EV, Kuligina E, Togo AV, Karpova MB,
Ulibina JM, Shutkin VA, et al. 'Comparison of extremes'
approach provides evidence against the modifying role of
NAT2 polymorphism in lung cancer susceptibil ity. Cancer
Lett. 2005 Apr 28;221(2):177-83.
316. Chiou HL, Wu MF, Chien WP, Cheng YW, Wong RH,
Chen CY, et al. NAT2 fast acetylator genotype is
associated with an increased risk of lung cancer among
never-smoking women in Taiwan. Cancer Lett. 2005 Jun
1;223(1):93-101.
317. Habalova V, Salagovic J, Kalina I, Stubna J. A pilot study
testing the genetic polymorphism of N-acetyltransferase
2 as a risk factor in lung cancer. Neoplasma.
2005;52(5):364-8.
318. Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A,
Matsumura S, et al. NAT2 and CYP1A2 polymorphisms
and lung cancer risk in relat ion to smoking status. Asian
Pac J Cancer Prev. 2007 Jan-Mar;8(1):103-8.
181
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
319. Cui D, Wang Z, Zhao E, Ma J, Lu W. NAT2 polymorphism
and lung cancer risk: a meta -analysis. Lung Cancer.
2011 Aug;73(2):153-7.
320. Shibuta J, Eto T, Kataoka A, Inoue H, Ueo H, Suzuki T,
et al. Genetic polymorphism of N-acetyltransferase 2 in
patients with esophageal cancer. Am J Gastroenterol.
2001 Dec;96(12):3419-24.
321. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B.
Association of genetic polymorphisms of N-
acetyltransferase 2 and susceptibil ity to esophageal
cancer in north Indian population. Cancer Invest. 2007
Aug;25(5):340-6.
322. Akbari MR, Malekzadeh R, Shakeri R, Nasrol lahzadeh D,
Foumani M, Sun Y, et al. Candidate gene association
study of esophageal squamous cell carcinoma in a high -
risk region in Iran. Cancer Res. 2009 Oct
15;69(20):7994-8000.
323. Malik MA, Upadhyay R, Modi DR, Zargar SA, Mittal B.
Association of NAT2 gene polymorphisms with
susceptibi l ity to esophageal and gastric cancers in the
Kashmir Valley. Arch Med Res. 2009 Jul;40(5):416 -23.
324. Ladero JM, Agundez JA, Olivera M, Lozano L,
Rodriguez-Lescure A, Diaz-Rubio M, et al. N-
acetyltransferase 2 single -nucleotide polymorphisms and
risk of gastric carcinoma. Eur J Clin Pharmacol. 2002
May;58(2):115-8.
325. Hong SH, Kim JW, Kim HG, Park IK, Ryoo JW, Lee CH,
et al. [Glutathione S-transferases (GSTM1, GSTT1 and
GSTP1) and N-acetyltransferase 2 polymorphisms and
the risk of gastric cancer]. J Prev Med Public Health.
2006 Mar;39(2):135-40.
326. Boissy RJ, Watson MA, Umbach DM, Deakin M, Elder J,
Strange RC, et al. A pilot study investigating the role of
182
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
NAT1 and NAT2 polymorphisms in gastric
adenocarcinoma. Int J Cancer. 2000 Aug 15;87(4):507 -
11.
327. Lan Q, Rothman N, Chow WH, Lissowska J, Doll MA,
Xiao GH, et al. No apparent associat ion between NAT1
and NAT2 genotypes and risk of stomach cancer. Cancer
Epidemiol Biomarkers Prev. 2003 Apr;12(4):384 -6.
328. Katoh T, Boissy R, Nagata N, Kitagawa K, Kuroda Y, Itoh
H, et al. Inherited polymorphism in the N -
acetyltransferase 1 (NAT1) and 2 (NAT2) genes and
susceptibi l ity to gastric and colorectal adenocarcinoma.
Int J Cancer. 2000 Jan 1;85(1):46-9.
329. Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura
K, Koizumi Y, et al. Association between dietary
heterocyclic amine levels, genetic polymorphisms of
NAT2, CYP1A1, and CYP1A2 and risk of stomach
cancer: a hospital -based case-control study in Japan.
Gastric Cancer. 2009;12(4):198-205.
330. Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, Al-Bahrani B,
Burney IA, Al-Madhani A, et al. NAT2 polymorphism in
Omani gastric cancer patients-risk predisposit ion and
clinicopathological associations. World J Gastroenterol.
2007 May 21;13(19):2697-702.
331. Zhang YW, Eom SY, Kim YD, Song YJ, Yun HY, Park JS,
et al. Effects of dietary factors and the NAT2 acetylator
status on gastric cancer in Koreans. Int J Cancer. 2009
Jul 1;125(1):139-45.
332. Zhong X, Hui C, Xiao-Ling W, Yan L, Na L. NAT2
polymorphism and gastric cancer susceptibi l ity: a meta -
analysis. Arch Med Res. 2010 May;41(4):275-80.
333. Lang NP, Chu DZ, Hunter CF, Kendall DC, Flammang TJ,
Kadlubar FF. Role of aromatic amine acetyltransferase in
183
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
human colorectal cancer. Arch Surg. 1986 Nov; 121(11):
1259-61.
334. Gil JP, Lechner MC. Increased frequency of wild -type
arylamine-N-acetyltransferase allele NAT2*4
homozygotes in Portuguese patients with colorectal
cancer. Carcinogenesis. 1998 Jan;19(1):37 -41.
335. I lett KF, David BM, Detchon P, Castleden WM, Kwa R.
Acetylat ion phenotype in colorectal carcinoma. Cancer
Res. 1987 Mar 1;47(5):1466-9.
336. Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I,
Luthra R, et al. Age-associated risk of cancer among
individuals with N-acetyltransferase 2 (NAT2) mutations
and mutations in DNA mismatch repair genes. Cancer
Res. 2001 Feb 15;61(4):1269-71.
337. Lee EJ, Zhao B, Seow-Choen F. Relationship between
polymorphism of N-acetyltransferase gene and
susceptibi l ity to colorectal carcinoma in a Chinese
population. Pharmacogenetics. 1998 Dec;8(6):513 -7.
338. Tamer L, Ercan B, Ates NA, Degirmenci U, Unlu A, Ates
C, et al. N-acetyltransferase 2 gene polymorphism in
patients with colorectal carcinoma. Ce ll Biochem Funct.
2006 Mar-Apr;24(2):131-5.
339. Kiss I, Nemeth A, Bogner B, Pajkos G, Orsos Z, Sandor
J, et al. Polymorphisms of glutathione -S-transferase and
arylamine N-acetyltransferase enzymes and
susceptibi l ity to colorectal cancer. Anticancer Res. 2004
Nov-Dec;24(6):3965-70.
340. Ladero JM, Gonzalez JF, Benitez J, Vargas E, Fernandez
MJ, Baki W, et al. Acetylator polymorphism in human
colorectal carcinoma. Cancer Res. 1991 Apr
15;51(8):2098-100.
341. Rodriguez JW, Kirl in WG, Ferguson RJ, Doll MA, Gray K,
Rustan TD, et al. Human acetylator genotype:
184
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
relat ionship to colorectal cancer incidence and arylamine
N-acetyltransferase expression in colon cytosol. Arch
Toxicol. 1993;67(7):445-52.
342. Shibuta K, Nakashima T, Abe M, Mashimo M, Mori M,
Ueo H, et al. Molecular genotyp ing for N-acetylat ion
polymorphism in Japanese patients with colorectal
cancer. Cancer. 1994 Dec 15;74(12):3108-12.
343. Probst-Hensch NM, Haile RW, Ingles SA, Longnecker
MP, Han CY, Lin BK, et al. Acetylat ion polymorphism and
prevalence of colorectal adenomas. Cancer Res. 1995
May 15;55(10):2017-20.
344. Spurr NK, Gough AC, Chinegwundoh FI, Smith CA.
Polymorphisms in drug-metabolizing enzymes as
modif iers of cancer risk. Clin Chem. 1995 Dec;41(12 Pt
2):1864-9.
345. Hubbard AL, Harrison DJ, Moyes C, Wyllie AH,
Cunningham C, Mannion E, et al. N-acetyltransferase 2
genotype in colorectal cancer and select ive gene
retention in cancers with chromosome 8p delet ions. Gut.
1997 Aug;41(2):229-34.
346. Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot
T, Garner RC, et al. Investigation of interact ion between
N-acetyltransferase 2 and heterocyclic amines as
potential r isk factors for colorectal cancer.
Carcinogenesis. 2003 Feb;24(2):275-82.
347. Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B,
Leppert M. NAT2, GSTM-1, cigarette smoking, and risk of
colon cancer. Cancer Epidemiol Biomarkers Prev. 1998
Dec;7(12):1079-84.
348. Tiemersma EW, Kampman E, Bueno de Mesquita HB,
Bunschoten A, van Schothorst EM, Kok FJ, et al. Meat
consumption, cigarette smoking, and genetic
susceptibi l ity in the etiology of colorectal cancer: results
185
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
from a Dutch prospective study. Cancer Causes Control.
2002 May;13(4):383-93.
349. Butler WJ, Ryan P, Roberts -Thomson IC. Metabolic
genotypes and risk for colorectal cancer. J Gastroenterol
Hepatol. 2001 Jun;16(6):631-5.
350. Ye Z, Parry JM. Meta-analysis of 20 case-control studies
on the N-acetyltransferase 2 acetylat ion status and
colorectal cancer risk. Med Sci Monit. 2002
Aug;8(8):CR558-65.
351. Yu MW, Pai CI, Yang SY, Hsiao TJ, Chang HC, Lin SM,
et al. Role of N-acetyltransferase polymorphisms in
hepatit is B related hepatocellular carcinoma: impact of
smoking on risk. Gut. 2000 Nov;47(5):703-9.
352. Gao JP, Huang YD, Lin JA, Zhu QC, Liang JP.
[Relat ionship between genetic polymorphisms of N -
acetyltransferase and susceptibi l ity to hepatocellular
carcinoma]. Zhonghua Gan Zang Bing Za Zhi. 2003
Jan;11(1):20-2.
353. Farker K, Schotte U, Scheele J, Hoffmann A. Impact of
N-acetyltransferase polymorphism (NAT2) in
hepatocellular carcinoma (HCC)--an investigation in a
department of surgical medicine. Exp Toxicol Pathol.
2003 Jun;54(5-6):387-91.
354. Agundez JA, Ladero JM, Olivera M, Lozano L,
Fernandez-Arquero M, de laConcha EG, et al. N -
acetyltransferase 2 polymorphism is not related to the
risk of advanced alcoholic l iver disease. Scand J
Gastroenterol. 2002 Jan;37(1):99-103.
355. Huang YS, Chern HD, Wu JC, Chao Y, Huang YH, Chang
FY, et al. Polymorphism of the N-acetyltransferase 2
gene, red meat intake, and the susceptibil ity of
hepatocellular carcinoma. Am J Gastroenterol. 2003
Jun;98(6):1417-22.
186
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
356. Gelatti U, Covolo L, Talamini R, Tagger A, Barbone F,
Martell i C, et al. N-Acetyltransferase-2, glutathione S-
transferase M1 and T1 genetic polymorphisms, cigarette
smoking and hepatocellular carcinoma: a case -control
study. Int J Cancer. 2005 Jun 10;115(2) :301-6.
357. Imaizumi T, Higaki Y, Hara M, Sakamoto T, Horita M,
Mizuta T, et al. Interact ion between cytochrome P450
1A2 genetic polymorphism and cigarette smoking on the
risk of hepatocellular carcinoma in a Japanese
population. Carcinogenesis. 2009 Oct;30(10 ):1729-34.
358. Ladero JM, Fernandez MJ, Palmeiro R, Munoz JJ, Jara
C, Lazaro C, et al. Hepatic acetylator polymorphism in
breast cancer patients. Oncology. 1987;44(6):341 -4.
359. Webster DJ, Flook D, Jenkins J, Hutchings A, Routledge
PA. Drug acetylat ion in breast cancer. Br J Cancer. 1989
Aug;60(2):236-7.
360. I lett KF, Detchon P, Ingram DM, Castleden WM.
Acetylat ion phenotype is not associated with breast
cancer. Cancer Res. 1990 Oct 15;50(20):6649-51.
361. Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA,
Pavlova MV. Acetylator phenotype in patients with breast
cancer. Oncology. 1978;35(4):185-8.
362. Sardas S, Cok I, Sardas OS, I lhan O, Karakaya AE.
Polymorphic N-acetylat ion capacity in breast cancer
patients. Int J Cancer. 1990 Dec 15;46(6):1138 -9.
363. Alberg AJ, Daudt A, Huang HY, Hoffman SC, Comstock
GW, Helzlsouer KJ, et al. N-acetyltransferase 2 (NAT2)
genotypes, cigarette smoking, and the risk of breast
cancer. Cancer Detect Prev. 2004;28(3):187-93.
364. Sil lanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma
VM, Uusitupa M, et al. NAT2 slow acetylator genotype as
an important modif ier of breast cancer r isk. Int J Cancer.
2005 Apr 20;114(4):579-84.
187
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
365. Huang CS, Chern HD, Shen CY, Hsu SM, Chang KJ.
Association between N-acetyltransferase 2 (NAT2)
genetic polymorphism and development of breast cancer
in post-menopausal Chinese women in Taiwan, an area
of great increase in breast cancer incidence. Int J
Cancer. 1999 Jul 19;82(2):175-9.
366. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG,
Chang-Claude J. Cigarette smoking, N-acetyltransferase
2 genotypes, and breast cancer r isk: pooled analysis and
meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008
Jan;17(1):15-26.
367. Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J,
Lopes C, et al. Acetylat ion genotype and the genetic
susceptibi l ity to prostate cancer in a southern European
population. Prostate. 2005 Aug 1;64(3):246-52.
368. Srivastava DS, Mittal RD. Genetic polymorphism of the
N-acetyltransferase 2 gene, and susceptibi l ity to prostate
cancer: a pi lot study in north Indian population. BMC
Urol. 2005;5:12.
369. Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T,
Muratani T, et al. N-acetyltransferase-2 gene
polymorphism as a possible biomarker for prostate
cancer in Japanese men. Int J Urol. 2003 Mar;10(3):
167-73.
370. Hein DW, Leff MA, Ishibe N, Sinha R, Frazier HA, Doll
MA, et al. Association of prostate cancer with rapid N -
acetyltransferase 1 (NAT1*10) in combination with slow
N-acetyltransferase 2 acetylator genotypes in a pilot
case-control study. Environ Mol Mutagen.
2002;40(3):161-7.
371. Agundez JA, Mart inez C, Olivera M, Gallardo L, Ladero
JM, Rosado C, et al. Expression in human prostate of
drug- and carcinogen-metabolizing enzymes: associat ion
188
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
with prostate cancer r isk. Br J Cancer. 1998
Nov;78(10):1361-7.
372. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO,
Johansson JE, Wadelius C, et al. Polymorphisms in
NAT2, CYP2D6, CYP2C19 and GSTP1 and their
association with prostate cancer. Pharmacogenetics.
1999 Jun;9(3):333-40.
373. Sharma S, Cao X, Wilkens LR, Yamamoto J, Lum-Jones
A, Henderson BE, et al. Well-done meat consumption,
NAT1 and NAT2 acetylator genotypes and prostate
cancer r isk: the multiethnic cohort study. Cancer
Epidemiol Biomarkers Prev. 2010 Jul;19(7):1866 -70.
374. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis
and visualization of LD and haplotype maps.
Bioinformatics. 2005 Jan 15;21(2):263 -5.
375. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J,
Blumenstiel B, et al. The structure of haplotype blocks in
the human genome. Science. 2002 Jun
21;296(5576):2225-9.
376. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL.
A new algorithm for haplotype-based associat ion
analysis: the Stochastic -EM algorithm. Ann Hum Genet.
2004 Mar;68(Pt 2):165-77.
377. Lieber CS. Cytochrome P-4502E1: its physiological and
pathological role. Physiol Rev. 1997 Apr;77(2):517-44.
378. Rendic S, Guengerich FP. Update information on drug
metabolism systems--2009, part II: summary of
information on the effects of diseases and environmental
factors on human cytochrome P450 (CYP) enzymes and
transporters. Curr Drug Metab. 2010 Jan;11(1):4-84.
379. Rendic S. Summary of information on human CYP
enzymes: human P450 metabolism data. Drug Metab
Rev. 2002 Feb-May;34(1-2):83-448.
189
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
380. Omiecinski CJ, Redlich CA, Costa P. Induction and
developmental expression of cytochrome P450IA1
messenger RNA in rat and human tissues: detection by
the polymerase chain reaction. Cancer Res. 1990 Jul
15;50(14):4315-21.
381. Hecht SS, Carmella SG, Murphy SE, Foiles PG, Chung
FL. Carcinogen biomarkers related to smoking and upper
aerodigestive tract cancer. J Cell Biochem Suppl.
1993;17F:27-35.
382. Schwarz D, Kisselev P, Cascorbi I, Schunck WH, Roots I.
Dif ferential metabolism of benzo[a]pyrene and
benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1
variants. Carcinogenesis. 2001 Mar;22(3):453 -9.
383. Georgiadis P, Topinka J, Vlachodimitropoulos D,
Stoikidou M, Gioka M, Stephanou G, et al. Interactions
between CYP1A1 polymorphisms and exposure to
environmental tobacco smoke in the modulation of
lymphocyte bulky DNA adducts and chromosomal
aberrat ions. Carcinogenesis. 2005 Jan;26(1):93 -101.
384. Sreelekha TT, Ramadas K, Pandey M, Thomas G,
Nalinakumari KR, Pil lai MR. Genetic polymorphism of
CYP1A1, GSTM1 and GSTT1 genes in Indian oral
cancer. Oral Oncol. 2001 Oct;37(7):593-8.
385. Sikdar N, Mahmud SA, Paul RR, Roy B. Polymorphism in
CYP1A1 and CYP2E1 genes and susceptibil ity to
leukoplakia in Indian tobacco users. Cancer Lett. 2003
May 30;195(1):33-42.
386. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt
U. Genetic polymorphisms of drug-metabolizing enzymes
and susceptibil ity to oral cavity cancer. Oral Oncol. 2002
Jul;38(5):486-90.
387. Kao SY, Wu CH, Lin SC, Yap SK, Chang CS, Wong YK,
et al. Genetic polymorphism of cytochrome P4501A1 and
190
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
susceptibi l ity to oral squamous cell carcinoma and oral
precancer lesions associated with smoking/betel use. J
Oral Pathol Med. 2002 Oct;31(9):505-11.
388. Xie H, Hou L, Shields PG, Winn DM, Gridley G, Bravo -
Otero E, et al. Metabolic polymorphisms, smoking, and
oral cancer in Puerto Rico. Oncol Res. 2004;14(6):
315-20.
389. Sugimura T, Kumimoto H, Tohnai I, Fukui T, Ma tsuo K,
Tsurusako S, et al. Gene-environment interact ion
involved in oral carcinogenesis: molecular
epidemiological study for metabolic and DNA repair gene
polymorphisms. J Oral Pathol Med. 2006 Jan;35(1):11 -8.
390. Marques CF, Koifman S, Koifman RJ, Boffetta P ,
Brennan P, Hatagima A. Inf luence of CYP1A1, CYP2E1,
GSTM3 and NAT2 genetic polymorphisms in oral cancer
susceptibi l ity: results from a case-control study in Rio de
Janeiro. Oral Oncol. 2006 Jul;42(6):632-7.
391. Leichsenring A, Losi -Guembarovski R, Maciel ME, Losi-
Guembarovski A, Oliveira BW, Ramos G, et al. CYP1A1
and GSTP1 polymorphisms in an oral cancer case -
control study. Braz J Med Biol Res. 2006 Dec; 39
(12):1569-74.
392. Losi-Guembarovski R, Colus IM, De Menezes RP,
Poliseli F, Chaves VN, Kuasne H, et al. Lack of
association among polymorphic xenobiotic -metabolizing
enzyme genotypes and the occurrence and progression
of oral carcinoma in a Brazil ian population. Anticancer
Res. 2008 Mar-Apr;28(2A):1023-8.
393. Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M.
Case-control study of oral and oropharyngeal cancer in
whites and genetic variation in eight metabolic enzymes.
Head Neck. 2008 Sep;30(9):1139-47.
191
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
394. Amtha R, Ching CS, Zain R, Razak IA, Basuki B, Roeslan
BO, et al. GSTM1, GSTT1 and CYP1A1 polymorphisms
and risk of oral cancer: a case-control study in Jakarta,
Indonesia. Asian Pac J Cancer Prev. 2009 Jan -Mar;
10(1):21-6.
395. Cha IH, Park JY, Chung WY, Choi MA, Kim HJ, Park KK.
Polymorphisms of CYP1A1 and GSTM1 genes and
susceptibi l ity to oral cancer. Yonsei Med J. 2007 Apr
30;48(2):233-9.
396. Anantharaman D, Chaubal PM, Kannan S, Bhisey RA,
Mahimkar MB. Susceptibil ity to oral cancer by genetic
polymorphisms at CYP1A1, GSTM1 and GSTT1 loci
among Indians: tobacco exposure as a risk modulator.
Carcinogenesis. 2007 Jul;28(7):1455-62.
397. Lee MY, Mukherjee N, Pakstis AJ, Khaliq S, Mohyuddin
A, Mehdi SQ, et al. Global patterns of variation in al lele
and haplotype frequencies and linkage disequil ibrium
across the CYP2E1 gene. Pharmacogenomics J. 2008
Oct;8(5):349-56.
398. Kidd KK, Morar B, Castiglione CM, Zhao H, Pakstis AJ,
Speed WC, et al. A global survey of haplotype
frequencies and l inkage disequil ibrium at the DRD2
locus. Hum Genet. 1998 Aug;103(2):211-27.
399. Bouchardy C, Hirvonen A, Coutelle C, Ward PJ, Dayer P,
Benhamou S. Role of alcohol dehydrogenase 3 and
cytochrome P-4502E1 genotypes in susceptibi l ity to
cancers of the upper aerodigestive tract. Int J Cancer.
2000 Sep 1;87(5):734-40.
400. Liu S, Park JY, Schantz SP, Stern JC, Lazarus P.
Elucidation of CYP2E1 5' regulatory RsaI/Pstl allelic
variants and their role in risk for oral cancer. Oral Oncol.
2001 Jul;37(5):437-45.
192
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
401. Zavras AI, Wu T, Laskaris G, Wang YF, Cartsos V, Segas
J, et al. Interaction between a single nucleotide
polymorphism in the alcohol dehydrogenase 3 gene,
alcohol consumption and oral cancer risk. Int J Cancer.
2002 Feb 1;97(4):526-30.
402. Liu TY, Chung YT, Wang PF, Chi CW, Hsieh LL. Safrole -
DNA adducts in human peripheral blood--an associat ion
with areca quid chewing and CYP2E1 polymorphisms.
Mutat Res. 2004 Apr 11;559(1-2):59-66.
403. Soya SS, Vinod T, Reddy KS, Gopalakrishnan S, Adithan
C. CYP2E1 polymorphisms and gene-environment
interactions in the risk of upper aerodigestive tract
cancers among Indians. Pharmacogenomics. 2008
May;9(5):551-60.
404. Tang K, Li Y, Zhang Z, Gu Y, Xiong Y, Feng G, et al. The
PstI/RsaI and DraI polymorphisms of CYP2E1 and head
and neck cancer risk: a meta-analysis based on 21 case-
control studies. BMC Cancer. 2010;10:575.
405. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup
H, Autrup JL, et al. Metabolic gene polymorphism
frequencies in control populations. Cancer Epidemiol
Biomarkers Prev. 2001 Dec;10(12):1239-48.
406. Wenghoefer M, Pesch B, Harth V, Broede P, Fronhoffs S,
Landt O, et al. Association between head and neck
cancer and microsomal epoxide hydrolase genotypes.
Arch Toxicol. 2003 Jan;77(1):37-41.
407. Varela-Lema L, Ruano-Ravina A, Juiz Crespo MA, Kelsey
KT, Loidi L, Barros-Dios JM. CYP1A1, mEH, and GSTM1
Polymophisms and Risk of Oral and Pharyngeal Cancer:
A Spanish Case-Control Study. J Oncol.
2008;2008:741310.
408. Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M,
Arzani D, De Lauretis A, et al. CYP1A1, CYP2E1,
193
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2
polymorphisms, smoking, consumption of alcohol and
fruit and vegetables and risk of head and neck cancer. J
Cancer Res Clin Oncol. 2008 Jan;134(1):93 -100.
409. Heckbert SR, Weiss NS, Hornung SK, Eaton DL,
Motulsky AG. Glutathione S-transferase and epoxide
hydrolase act ivity in human leukocytes in relation to r isk
of lung cancer and other smoking-related cancers. J Natl
Cancer Inst. 1992 Mar 18;84(6):414-22.
410. Timofeeva M, Kropp S, Sauter W, Beckmann L,
Rosenberger A, I l l ig T, et al. Genetic polymorphisms of
MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk
factors of early-onset lung cancer. Int J Cancer. 2010
Oct 1;127(7):1547-61.
411. Robien K, Curt in K, Ulrich CM, Bigler J, Samowitz W,
Caan B, et al. Microsomal epoxide hydrolase
polymorphisms are not associated with colon cancer r isk.
Cancer Epidemiol Biomarkers Prev. 2005
May;14(5):1350-2.
412. Voho A, Metsola K, Antti la S, Impivaara O, Jarvisalo J,
Vainio H, et al. EPHX1 gene polymorphisms and
individual susceptibil ity to lung cancer. Cancer Lett. 2006
Jun 8;237(1):102-8.
413. Wu X, Gwyn K, Amos CI, Makan N, Hong WK, Spitz MR.
The associat ion of microsomal epoxide hydro lase
polymorphisms and lung cancer risk in African -Americans
and Mexican-Americans. Carcinogenesis. 2001 Jun;
22(6):923-8.
414. Lee J, Nordestgaard BG, Dahl M. EPHX1 polymorphisms,
COPD and asthma in 47,000 individuals and in meta -
analysis. Eur Respir J. 2010 Jun 1.
415. Chappell S, Daly L, Morgan K, Guetta -Baranes T, Roca
J, Rabinovich R, et al. Genetic variants of microsomal
194
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
epoxide hydrolase and glutamate-cysteine l igase in
COPD. Eur Respir J. 2008 Oct;32(4):931-7.
416. Yang X, Liang SH, Weyant DM, Lazarus P, Gallagher CJ,
Omiecinski CJ. The expression of human microsomal
epoxide hydrolase is predominantly driven by a
genetical ly polymorphic far upstream promoter. J
Pharmacol Exp Ther. 2009 Jul;330(1):23-30.
417. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism
of isoniazid in man as related to the occurrence of
peripheral neurit is. Am Rev Tuberc. 1954 Aug;70(2):
266-73.
418. Weber WW, Hein DW. N-acetylat ion pharmacogenetics.
Pharmacol Rev. 1985 Mar;37(1):25-79.
419. Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP.
Association of NAT2, GSTM1, GSTT1, CYP2A6, and
CYP2A13 gene polymorphisms with susceptibi l i ty and
clinicopathologic characteristics of bladder cancer in
Central China. Cancer Detect Prev. 2009;32(5 -6):416-23.
420. Yoshida K, Osawa K, Kasahara M, Miyaishi A, Nakanishi
K, Hayamizu S, et al. Association of CYP1A1, CYP1A2,
GSTM1 and NAT2 gene polymorphisms with colorectal
cancer and smoking. Asian Pac J Cancer Prev. 2007 Jul -
Sep;8(3):438-44.
421. Nikishina MV, Vavilin VA, Makarova SI, Lyakhovich VV.
Analysis of associations of NAT2 gene polymorphisms
with the risk of lung cancer. Bull Exp Biol Med. 2007
Jan;143(1):83-6.
422. Drozdz M, Gierek T, Jendryczko A, Pilch J, Piekarska J.
N-acetyltransferase phenotype of patients with cancer of
the larynx. Neoplasma. 1987;34(4):481 -4.
423. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ,
Suarez C, Coto E. Genetic polymorphism of N-
acetyltransferase-2, glutathione S-transferase-M1, and
195
Gene polymorphism and risk of oral cancer in a South Indian population – a case control study
cytochromes P450IIE1 and P450IID6 in the susceptibi l ity
to head and neck cancer. J Clin Pathol. 1998
Apr;51(4):294-8.
424. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I.
Association of arylamine N-acetyltransferases NAT1 and
NAT2 genotypes to laryngeal cancer risk.
Pharmacogenetics. 1999 Feb;9(1):103 -11.
425. Jourenkova-Mironova N, Wikman H, Bouchardy C,
Mitrunen K, Dayer P, Benhamou S, et al. Role of
arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2)
genotypes in susceptibil ity to oral/pharyngeal and
laryngeal cancers. Pharmacogenetics. 1999 Aug; 9(4):
533-7.
426. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell
DA. A pilot study testing the associat ion between N-
acetyltransferases 1 and 2 and risk of oral squamous cell
carcinoma in Japanese people. Carcinogenesis. 1998
Oct;19(10):1803-7.
427. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M,
Kaneko K, et al. Genetic polymorphisms of drug-
metabolizing enzymes and susceptibil ity to head -and-
neck squamous-cell carcinoma. Int J Cancer. 1999 Mar
1;80(5):685-8.
428. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL,
Schwartz SM. N-Acetyltransferase 2 polymorphisms,
cigarette smoking and alcohol consumption, and oral
squamous cell cancer r isk. Carcinogenesis. 2001
Dec;22(12):1993-9.
429. Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A,
Lagiou P, et al. Genetic associations of 115
polymorphisms with cancers of the upper aerodigestive
tract across 10 European countries: the ARCAGE project.
Cancer Res. 2009 Apr 1;69(7):2956-65.